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Theoretical studies focusing on the nature of landscapes that correlate molecular 
sequences to molecular function have mainly been carried out in silico due to the vast 
amounts of data that are needed for analysis. In vitro selections of aptamers are a good 
model system to study theoretical questions at a experimental level.  With the 
introduction of robotic platforms that conduct in vitro selections, it is now capable of 
producing significant amounts of data in a short time, making theoretical modeling with 
real experimental data attainable.  
I will be using a Biomek 2000 Laboratory Automation Workstation to carry out 
multiple in vitro nucleic acid selections in parallel. I will explore the sequence space to 
examine whether existing in vitro selection systems are optimal at isolating the best 
winning species. New methods will be introduced that will allow for the selection of 
identical targets with identical pools free of cross contamination on the open robotic 
system. This will open the doors to further conduct selections against other identical or 
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highly similar targets, such as complex cellular targets. 
Finally, I will investigate the methods to improve the effectiveness at isolating 
aptamers against the highly complex lung cancer cell lines. These targets are highly 
challenging for isolating specific aptamers because of the great diversity of biomarkers 
found among them. Moreover, their highly morphological similarity of the cultured cells 
makes selections for specific aptamers very difficult. I explore the different methods that 
will allow for the generation of aptamers that can distinguish between non-small cell lung 
cancer and small cell lung cancer, and between non-small cell lung cancer and normal 
lung cells. Fine-tuning of this process is essential at transferring this process to automated 
platforms for large-scale generation of biosensors against tumor biomarkers. 
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CHAPTER 1: INTRODUCTION 
BACKGROUND OF APTAMERS 
It has been over 15 years since the modern version of in vitro selection was 
codified [1, 2], and during that time, aptamers have been selected against an extremely 
wide variety of targets ranging from small inorganic molecules to whole organisms [3-6]. 
In part because aptamers have proven to have high affinities (picomolar to nanomolar 
dissociation constants) for their cognate targets and specificities that are comparable to 
those of monoclonal antibodies the development of aptamer therapeutics has now begun 
to take off.  Table 1.1 summarizes the important differences between aptamers and 
antibodies and the advantages that each one confers. Figure 1.1 denotes the immense size 
difference between an aptamer and an antibody. 
Numerous aptamers have been selected against therapeutic targets such as IgE, 
IFN-g, alpha-thrombin, PTPase, and others, and have shown great efficacy in tissue 
culture experiments and animal models.  In earlier years, an anti-thrombin aptamer was 
used in place of heparin for anti-coagulation during heart bypass surgery in canines [7], 
while aptamers against inflammation factor human neutrophil elastase (hNE) were shown 
to significantly reduce lung inflammation in rats and had better specificity for their target 
than an anti-elastase IgG control [8].  Several aptamers have just begun to reach the 
clinic.  This number should increase greatly in coming years, in large part because 
methods for the delivery of nucleic acid therapeutics are now being developed, and 
because the pharmacokinetic properties of aptamers have begun to be explored in detail.   
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Table 1.1. The table depicts the differences between aptamers and antibodies from their 
selection process to their applications. 
 
THE SELECTION PROCESS 
An initial pool of about 10
14-15
 different nucleic acids species is incubated with 
the target of interest. After an arbitrary incubation time, the unbound nucleic acid species 
are partitioned away from those bound to the target. The bound aptamers are eluted from 
the target and further amplified through a series of amplification steps producing an 
enriched pool to be carried into the next round of selection. This iterative process is 
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repeated until an increase in pool binding is observed. The process of selection is 
illustrated in Figure 1.2. 
 
 
Figure 1.1.  Antibody / Aptamer Size Comparison.  An estimated comparison of the 
size difference between an antibody (human IgG) and a selected aptamer (anti-thrombin 
DNA aptamer) is shown with space-filling models of both.  It should be noted that the 
anti-thrombin aptamer is only 15 residues in length [9], while the anti-gp120 aptamer that 





Figure 1.1. Selection Schema. A random RNA pool containing ~1013 – 1015 unique 
individual sequences is incubated with a target. The pool / target complex is washed in 
order to remove low-affinity nucleic acid. Next, high-affinity RNA is eluted from the 
target and reversed transcribed, PCR amplified and transcribed. This lower diversity pool 
is then incubated with a new aliquot of the selection target, and the selection cycle begins 
again.  
APTAMERS IN THEORETICAL STUDIES 
 RNA aptamers targeted to small molecules have served as model systems for the 
study of evolutionary theories of macromolecular interactions. Aptamers are great 
candidates for theoretical studies because they can be subjected to mutational pressures 
that affect one single property such as binding. The Lehman group has shown that in vitro 
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selection can be used to explore the topography of fitness landscapes for the sequence 
space surrounding a given RNA, either for its original activity or for acquisition of a new 
activity [10]. They evolved in vitro a group of ribozymes and found that these molecules 
had smooth phenotypic landscape, in the presence of a rugged genotypic landscape [10]. 
Structural features that contribute to ligand binding make RNA aptamers the choice 
molecule for these studies. The Famulok group selected aptamers to the amino acid 
citrulline, and then evolved these aptamers to bind to a related molecule arginine [11]. 
Through only three mutations, aptamers to arginine were isolated, and these aptamers had 
secondary structures similar to citrulline aptamers [11]. These mutations not only 
introduced codons for arginine but were later shown by NMR to make close contact with 
the target [12].  Dopamine-binding RNAs were evolved to recognize another related 
amino acid tyrosine, however, in contrast to the arginine/citrulline aptamers, more 
mutations were needed to change the specificity from dopamine to tyrosine leading to 
unrelated RNA structures [13]. These studies focused primarily on the end products of 
the selection, without addressing evolutionary intermediates. Local accessibility of new 
functions between related sequences of aptamers can be revealed through a systematic 
examination of a defined sequence space. 
PROBING SEQUENCE SPACE  
Theoretical and experimental analyses have offered complementary perspectives 
on neutral evolutionary models by demonstrating that sequences differing by only one or 
two positions (Hamming distance = 1 or 2) can be structurally equivalent, thereby 
forming neutral networks in sequence space [14-16]. Neutral network in structural 
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sequence space referred to RNAs of a fixed length that possessed similar or related 
secondary structures [16]. These secondary structures served as the bridge for unrelated 
regions of sequence.  To travel through sequence space, sequences will travel through a 
structural neutral path by the accumulation of mutations. A single sequence capable of 
two distinct functions is said to represent the intersection between two neutral networks. 
The Bartel group found the existence of an intersection sequence by evolving a ribozyme 
with dual catalytic functions [17]. This ribozyme represented the neutral path that led to 
two evolutionary distinct ribozymes. The RNAs’ ability to adopt multiple conformations 
makes intersection sequences highly probable when the secondary structure is the 
phenotypic criterion. 
 Held et al. provided first detailed examination of the complete intervening 
sequence space between related but functionally distinct aptamer RNAs [18]. They 
showed the conversion of flavin-binding aptamers to a diverse collection of GMP-
binding sequences through in vitro selections. They probed the fitness landscapes 
between two FAD aptamers and between an FAD aptamer and a GMP aptamer by 
assessing ligand binding by all evolutionary intermediates. Their results suggest that 
RNA sequence space contains many unrelated solutions to the problem of GMP binding 
and that some GMP aptamers are very near in sequence space to neutral networks for 
FAD-binding function. When they carried out structural analysis of closely related FAD-
binding and GMP-binding aptamers they observed very few structural differences until 
the final switch in target recognition was attained. These findings show how an FAD-
binding phenotype could be maintained in a rugged landscape through mutational drift 
along a neutral network until the critical “off-path” mutations would force the transition 
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in the structure to the nearby GMP-binding phenotype. All these findings further support 
the neutral evolutionary theory. 
Since aptamers can serve as ideal candidates for theoretical studies such as 
probing sequence space, generation of vast amounts of data would be ideal for the task. 
Generating enough data for this type of study might have been considered impossible, 
however with the advent of automated selection [19, 20], achieving this goal is not so far 
fetched with slight improvements and careful planning. 
CELL SURFACE SELECTIONS 
Reagents that can recognize vast amount of cell surface biomarkers of 
tumorigenic cells are crucial in the early detection and improved prognosis of the disease.  
Cell surface signal transduction proteins such as receptor tyrosine kinases (RTKs) play a 
key role in regulating cell growth and proliferation in several different types of cancers 
[21], making them attractive targets for ameliorating tumor progression.  Mutations in the 
RTK known as RET are responsible for the onset of both Type 2A and 2B Multiple 
Endocrine Neoplasia (MEN) syndrome and familial medullary thyroid carcinoma [22, 
23].  Nuclease-resistant RNA aptamers specific to mutant RET were obtained by carrying 
out selections against RET-expressing cells [24]. These aptamers were shown to inhibit 
the activity of the protein on the surface and to block downstream signaling.  Based on 
these results, it was hypothesized that the aptamer functioned by preventing the formation 
of the RET dimer.  Since numerous RTKs and cell surface receptors function as dimers or 
oligomers, additional aptamers might also prove to be inhibitory by a similarly elegant 
mechanism. 
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Other extracellular proteins involved in signal transduction can be targeted.  For 
example, increased expression of alpha-beta-3 integrin can lead to angiogenesis and is 
correlated with multiple human tumors such as melanoma [25].  An aptamer selected 
against the alpha-beta-3 integrin has been shown to inhibit angiogenesis in vasculature by 
down-regulating integrin-activated signaling pathways [26]. 
Aptamers can not only be selected against purified targets or antigens, but also 
against heterogeneous mixtures of targets, such as whole cells (recently reviewed by Yan 
et al. [6]).  Selections against complex targets allow aptamers to be generated even when 
biomarkers are not known in advance, and should facilitate the identification of new 
biomarkers.  For example, aptamers targeting human osteoblasts from an osteosarcoma 
tissue were selected and used to coat the tissue culture plate wall to directly capture the 
osteoblasts in solution [27].   
Negative selection procedures with whole cells can yield aptamers that finely 
discriminate against different cell types.  For example, the selection against the RET 
receptor tyrosine kinase described above included negative selections against cells that 
did not include the RET-expressing vector and against cells that expressed a mutant form 
of RET [24].  In one of the most intriguing examples to date, Homann and Goringer [28] 
were able to select aptamers against whole trypanosomes; and, the target was localized to 
the flagellar pocket by photo-crosslinking experiments.  Later selection experiments that 
specifically targeted VSG also yielded aptamers that could bind tightly and specifically to 
the surface of the parasite [29].  Complex targets are not restricted to only cells or 
organisms; selections have been carried out that targeted plasma and aptamers were 
coordinately isolated against 14 different plasma proteins [30].  
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Homann and Goringer [28] selected aptamers against whole trypanosomes; these 
were eventually found to bind to the variant surface glycoprotein.  The target was initially 
identified by photo-crosslinking experiments, which allowed the determination of its size; 
fluorescently labeled aptamers could be localized to the flagellar pocket of the organism.  
It was suspected that the protein target was in the variant surface glycoprotein (VSG), 
and later selection experiments that specifically targeted VSG also yielded aptamers that 
could bind tightly and specifically to the surface of the parasite [29]. Similarly, Pan et al. 
[31] generated both RNA and modified nuclease-resistant RNA aptamers to Rous 
sarcoma virus (RSV).  These aptamers were able to significantly reduce the rate of RSV 
infection in a quail fibrosarcoma cell line at a concentration of only 20 nM in serum.   
 The ability to select aptamers against simple or complex targets and their 
seemingly pluripotent binding abilities make them excellent reagents for the study, 
diagnosis, and perhaps even therapy of cancers, as reviewed by Cerchia et al. [32].  In 
fact, selection experiments have yielded RNA and DNA aptamers that can bind to cell 
surface targets on tumors [33-35].   In each instance, the aptamers were able to 
selectively bind transformed cells but not normal cells.  For example, Hicke et al.,[34] 
targeted human U251 glioblastoma cells with a 2’-fluoropyrimidine, modified RNA pool.  
Selected, modified RNA aptamers were found to bind the extracellular matrix protein 
tenascin-C (TN-C), a protein that is believed to be a hallmark for the onset and metastasis 
of cancer.  The selected aptamers formed complexes with TN-C and had a dissociation 
constant of 5 nM.  The aptamers also bound tumor tissue expressing tenascin-C, but did 
not bind tissue that lacked TN-C.  In fact, the aptamer was also able to discriminate (by 
20-fold) against mouse TN-C, even though this protein shares 98% sequence identity 
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with the human protein.   Other selection experiments have also revealed that aptamers 
are frequently highly species specific (see, for example, White et al., 2001 [36]).   
 In a second example, Lupold et al. [35] targeted prostate-specific membrane 
antigen (PSMA), a membrane-bound glycoprotein that is found in prostatic epithelial 
cells and that is overexpressed by prostate cancers.  In fact, its detection in increased 
quantities is considered a hallmark of the disease.  PSMA has been shown to have folate 
hydrolase activity as well as peptidase activity although its actual biological function is 
not known [37].  Two aptamers were selected from a 2’-fluoropyrimidine, modified RNA 
library that spanned 40 random sequence positions.  The aptamers were distinct from one 
another and likely bound different epitopes of the PSMA antigen.  The aptamers could 
inhibit the peptidase activity of PSMA with Ki values in the 2-10 nM range.  
Fluorescently labeled aptamers were also shown to bind to a prostate tumor line (LNCaP) 
that normally overexpresses PSMA, but not to PC-3 cells, a different prostate tumor line 
that does not express the antigen.  
 Finally, Blank et al. [33] carried out a selection against rat endothelial cells 
immortalized with adenovirus, and isolated a single-stranded DNA aptamer that proved 
to be specific for glioblastoma.  The aptamer was found to bind to the protein pigpen, 
which plays a role in angiogenesis by regulating endothelial cell proliferation.  Pigpen 
expression is up-regulated in actively dividing cells and is down-regulated as they 
become confluent, suggesting that pigpen helps regulate endothelial cell differentiation 
[38].  Pigpen has both a transcription activation domain as well as RNA binding motifs 
which are thought to interact with positive cell cycle regulators.   Given the way in which 
the selection was carried out, it therefore appears as though pigpen is a transcription 
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regulator but may also be expressed on the surface of vascular endothelial cells.  This 
hypothesis remains the subject of active investigation.  Nonetheless, it is true that the 
aptamer could be used to specifically label microvessels surrounding rat glioblastoma, 
but not microvessels in normal, mature brain vasculature.  As was the case with anti-
PSMA aptamers, the anti-pigpen aptamers could be fluorescently labeled and used for 
contrast staining of transformed cells versus normal cells.   
CONCLUSION 
 Aptamers have interesting properties relative both to protein therapeutics, such as 
antibodies, and to small organic drugs.  Moreover, they possess qualities that make them 
great candidates for theoretical investigations. I will be using aptamers as the model of 
choice to better understand the implications behind the selection process. Many questions 
remain unanswered about this process. I will design selections in a way that will allow 
me to probe different starting points in sequence space and investigate whether the 
trajectory the molecules take correspond to each other. I will also investigate whether 
different starting points lead to different end points. The results of this study will shed 
light onto the question whether conventional in vitro selection process utilized is optimal 
for attaining the best binding species However, before this can take place, certain 
modifications to the automation system are essential. Issues of cross-contamination of 
selections using the same RNA pool against the same target will have to be addressed 
initially. This will not only aid in theoretical studies, but it is crucial for future selections 
against similar but more sensitive cellular targets using the same selection pools. 
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As the first aptamer therapeutics make their way into clinical practice 
uncertainties surrounding this class of therapeutic compounds will dissipate, and new 
aptamers should find increasing use as drugs, a progression that will be aided by new 
synthesis chemistries and new selection methodologies. Aptamers are slowly finding 
their way into cancer biology research as a diagnostics tool and site specific delivery [39-
41]. Because of their increasingly important role in cancer research, and the importance 
of finding biomarkers for early detection, cell surface selection methods will be 
conducted.  
Three lung tumor cell lines that differ in their Epidermal Growth Factor Receptor 
(EGFR) expression were chosen as targets for selection.  NCI-H358 is from a non-small 
cell lung cancer and expresses wild type EGFR.  NCI-1650 is from a bronchoalveolar 
carcinoma and expresses a mutant form of EGFR (in-frame deletion delE746-A750). 
NCIH526 is from a small cell lung cancer (SCLC) cell lines and expresses low to 
undetectable levels of EGFR.   The first two lines are adherent, but NCIH526 is a 
suspension culture.  Selection of aptamers against these three lines will serve several 
purposes:  first, it will potentially demonstrate that aptamers against cell surfaces can be 
used to differentiate various types of lung tumor cells.  Second, aptamers may be derived 
that recognize particular types or levels of EGFR, an important tumor marker.  And 
finally, selection methods that target both adherent and suspension cells will be 
developed. Methods for tailoring specific aptamer for the targets of interest will be 
investigated and once an optimal method is obtained, it can be translated to the 
“contamination-free” automated platform that will be developed.
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CHAPTER 2: APTAMER DATABASE 
INTRODUCTION 
PUBLIC DATABASES AVAILABLE 
 
The number of publicly available databases collectively constitutes a rich and 
ever-increasing source of biological information [1]. The information available is not 
limited to genomic sequences with different information obtained from experiments and 
computational experiments. The annotations include the location of introns, exons, and 
the existence of transcripts with splice variants. Databases that include protein-related 
information is also widespread and they contain valuable information about the 3D 
structures, base pair interactions, and other important information that is useful for any 
scholar. In order to facilitate data extraction by users, most databases are extensively 
cross-referenced and used highly efficient search tools that are developed mainly for 
sequence-based searches. 
Some of the best known databases include the Gene Ontology (GO) Consortium, 
which contains information such as biological processes, molecular functions and cellular 
components [2]. Another useful database that focus on cellular processes and provide 
their information as interconnected pathways with computer representations is the Kyoto 
Encyclopedia Genes and Genome (KEGG) [3]. Other popular databases focus on 
microarray data [4, 5]. More specialized databases include those that focus on individual 
organisms such as such D. melanogaster, A. Taliana and C. elegans. [6-8]. 
 
17 
THE APTAMER DATABASE 
 
Functional nucleic acids can be selected from random sequence libraries.  In 
general, in vitro selection mimics natural selection, in that a pool of heritable diversity is 
generated (typically by chemical synthesis). The pool is sieved for binding or catalysis, 
and successful variants are preferentially amplified by some combination of reverse 
transcription, PCR, and in vitro transcription [9-13].  This process has also been 
described as the Systematic Evolution of Ligands by EXponential enrichment or SELEX 
[14].  Nucleic acid binding species generated by in vitro selection have been referred to 
as aptamers [15].  Aptamers can be RNA, modified RNA, single-stranded DNA, or 
double-stranded DNA and have been selected to bind targets ranging from small organic 
molecules to entire organisms.  Novel nucleic acid catalysts can also be selected, in 
general by modifying selection schemes so that variants that make or break covalent 
(rather than non-covalent) bonds are selectively retained in the population [16-19].  Since 
its introduction over ten years ago, in vitro selection has been widely adopted as a tool for 
the development of research reagents. This method shows promise for the generation of 
diagnostic and therapeutic agents [10, 20-22].  
The Aptamer Database is not only extremely useful both for identifying what 
aptamers and unnatural ribozymes already exist, but also for garnering information about 
in vitro selection experiments as a whole and for better understanding the distribution of 
functional nucleic acids in sequence space and the topographies of fitness landscapes.  
We have collaborated with theoretical biologists for several years on analyses of the 
Aptamer Database, and now wish to make this resource much more widely available.  In 
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addition, comparative sequence analysis tools should facilitate mappings between natural 
and unnatural sequence spaces, ultimately providing insights into both.  For example, 
selected transcription factor binding sites have proven to be similar to and predictive of 
natural transcription factor binding sites [23-26]. 
Like other types of sequence data, the amount of sequence data generated by in 
vitro selection experiments has been accumulating exponentially.  Because the sheer 
number and diversity of selection experiments has risen over the years; it is essential to 
gather all the sequence data into a comprehensive, continuously updated database.  
Unfortunately, Genbank and other sequence databases do not have extensive collections 
of non-natural sequences, and journals do not typically require the entry of non-natural 
sequences into these databases.  We have now privately maintained the Aptamer 
Database for five years, and expanded its content on a monthly basis. 
Another database, the SELEX_DB, also contains some information from in vitro 
selection experiments [27, 28].  However, the SELEX_DB focuses on in vitro selection 
experiments that have helped define natural DNA and RNA recognition sites for proteins, 
rather than including the entire repertoire of in vitro selection experiments.  While there 
is some overlap between the two sites, the Aptamer Database is in general more 
complete, and contains entries from over 300 published in vitro selection experiments; in 
contrast SELEX_DB has entries from only 116 publications.  The focus of the 
SELEX_DB on known binding sites ultimately limits its utility for exploring connections 
between selection experiments and the natural world.  For example, natural aptamers that 
can bind ligands and regulate gene expression (so-called ‘riboswitches’) have been 
discovered by Breaker and his co-workers [29-31], and the sequences of riboswitches and 
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We wanted to create a database that would be easily accessible containing the 
essential information from in vitro selections carried out up-to-date.  The Aptamer 
Database contains sequences drawn from over 300 published in vitro selection 
experiments.  Each entry is described by the following fields: Author (last name, first 
name, and middle initial for each author); Title; Medline (accession number and a direct 
link to the Pubmed record); Target name (the name of the ligand that was used for the 
selection of an aptamer); Target type (the classifications we have chosen are proteins, 
peptides, nucleic acids, organic molecules, inorganic molecules or other); Journal (year, 
volume, issue, pages); Pool category (DNA or RNA); Modified (Y or N) (indicates 
whether the nucleic acid pool used in a selection was natural or modified); Buffer 
conditions; Template description (describes the length of the random region); Template 
sequence (describes the primer binding sites); and Sequences (the list of all the sequences 
isolated from the selection).   
 References to and sequences from in vitro selection experiments can be searched by 
providing specific queries relevant to one of the fields such as author name, target name, 
type of target, type of pool, and so forth, as shown in Figure 2.1A.  In this example the 
database is being searched for a given Target, thrombin [32].  Once the user makes a 
selection, the results will show all the relevant papers that match the criteria supplied as 
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shown in Figure 2.1B. The user can then hone in on the information in one or more 




Figure 2.1A. Aptamer Search Page.  Users can search the database by supplying a 
broad range of terms such as Author’s last name, Title keywords, or Target name.  
Records in the database can also be searched based on combination of different criteria 
(such as the Target type, the journal or year a particular record was published, and the 
type of pool (RNA or DNA) that was used to carry out the selection).  In the example 
shown, the term “thrombin” is supplied in the Target name dialogue box. 
 
  The database is updated monthly as new papers on the in vitro selection of 
aptamers or unnatural ribozymes become available.  Initially, older papers were chosen 
for entry based on using the keywords “aptamer” and “SELEX” with the Pubmed search 
engine.  Additional searches with the same keywords were also conducted using the 
SciFinder search engine (available at http://www.cas.org/SCIFINDER/scicover2.html).  
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Pubcrawler [33] is utilized for monthly updates using the keywords “aptamer” and 
“SELEX.” At present, data is entered manually.  Each sequence is entered in the database 
template twice and the entries are compared to ensure accuracy. While I have attempted 
to use optical character recognition (OCR) software, it has proven both inefficient and 
inaccurate, since the formats of published data are very different from one another. 
 
 
Figure 2.1B. Results of the Search Page.. A display of the multiple records that were 
found for the target “thrombin.”   
 
 
While I have attempted to make the database as complete as possible, some selection 
papers have been published without appropriate or standard keywords, and thus that some 
literature may have been overlooked.  I have included older references as they are 
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brought to my attention.  In addition, one of the prime considerations in publishing the 
Aptamer Database is to facilitate the entry of data by authors and users, and have 
provided a template for data entry available for download at 
http://aptamer.icmb.utexas/submit) [34].  Only data that has been peer-reviewed in 
conjunction with a publication will be accepted in the database. 
 
 
Figure 2.1C. Sequences from the Search.  Any one of the recovered records has an 
associated set of aptamer or ribozyme sequences.  For the “thrombin” example, the 
sequences from the original single-stranded DNA selection that targeted thrombin [32] 
are shown.  There is also more detailed information about the selection that produced 
these sequences, such as the nature of the pool and buffer conditions used for selection. 
 
DATABASE CONTENT DISTRIBUTION 
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 Once the information was stored in the database, it was necessary to look into the 
distribution of the data that was available to the public. It allowed for a glimpse to the 
overall amount of in vitro selection data based on the type of selection that have been 
conducted.  First step was to investigate the distribution of the different targets that have 
been selected. Figure 2.2 shows the amount of different target-types that have aptamers 
selected. Almost half of the targets fall under the “protein” family.  Other classifications 
include inorganic molecules, organic molecules, nucleic acids, peptides, and “other” 
which include whole organisms, whole cells, and others molecules that cannot be 
classified under the other existing categories. 
 
Figure 2.2. Distribution of Selected Targets that are Found in the Database. Most of the 
targets that have been utilized are proteins. Targets that fall under the “other” category 
include whole organisms and mammalian cells. 
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The next set of information of interest was the number of aptamers that were 
found in the database for each target category as shown in Figure 2.3. Once a clear 
understanding of the distribution of the aptamers was available, we wanted to investigate 
whether most of the aptamers that were selected were RNA or DNA. Interestingly, most 
of the selections that have been carried out are RNA aptamer selections as shown in 
Figure 2.4. They include modified RNA selections. The reason for the abundant number 
of RNA based selections can be attributed to the fact that the method for RNA selections 
was introduced before that of DNA. Also, for therapeutic purposes, RNA molecules do 
not have the risks associated with DNA such as genome integration into the host. 
 
Figure 2.3. Distribution of Aptamers for each Target Group. As shown in the figure, 
there is more aptamers target to proteins that any other group. This can be attributed to 





Figure 2.4. Distribution of RNA Versus DNA Aptamers.  The number of RNA 
aptamers that have been selected is more abundant than of DNA aptamers. Many 
different factors may contribute to such a disparity such as the selection methods as well 
as the versatility of RNA aptamers. 
CHAOS GAME REPRESENTATION OF THE APTAMER DATABASE 
 
Once the distribution of RNA versus DNA aptamers was obtained. The next 
challenge was to represent the sequence data from the database in a clear and concise 
manner. One of the greatest challenges is visual data representation of vast amounts of 
sequence data. A very interesting way that we have found to represent data is known as 
the Chaos Game Representation (CGR).  Jeffrey introduced CGR in 1990 as a tool for 
studying the "non-randomness" of genomic sequences [35]. It used primary sequence as 
data input and it would place the sequence within a quadrant based on its nucleotide 
content. Figure 2.5 shows the CGR representation of all DNA and RNA aptamers 
irrespective of each other. The quadrant has four vertices each represented by one of the 
four nucleotides.  Within the square images obtained by the method each aptamer is 
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represented by a dot. Sequences are placed based on their nucleotide composition. The 
CGR quadrants are graphed so that the lower (A:T) and upper (G:C) halves indicate the 
base composition and the diagonals indicate the purine/pyrimidine composition. 
Additional sub-quadrants can be further subdivided containing sequences ending with a 
given di-nucleotide. This will allow the sequences that differ only in one letter to be 
located in adjacent quadrants. The CGR representation depicts clearly that selected DNA 
aptamers were AT rich as opposed to RNA aptamers that seemed to have an even 
representation in terms of nucleotide composition. The advantage of conducting this type 
of graphical representation is that it does not depend on for sequence length, which is a 
challenge for comparing aptamer sequences. 
 
 
Figure 2.5. CGR Representation of Aptamers. Sequences from the database are 
extracted and divided into DNA and RNA aptamers. The nucleotide composition for each 
category is analyzed and projected. The analysis is based on an algorithm described by 
the Fletcher group in 2001 [36]. DNA aptamers are skewed towards AT rich as opposed 
to RNA aptamers that remains relatively uniform in ACTG composition. 
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GLOBAL REPRESENTATION OF THE APTAMER DATABASE 
 
To get an overall distribution of all the sequences in the database, a space-filled 
model of aptamer position relative to each other was created. A global analysis of the 
aptamers was conducted to determine the distribution of the sequences in space. Using a 
Basic Local Alignment Search Tool (BLAST) algorithm, with the default settings, 
pairwise comparisons of all the aptamer sequences were conducted. The aptamers were 
positioned on the map according to sequence similarity. The results were visualized using 
a large graph layout (LGL) to visualize the extensive map summarizing the results of the 
sequence comparisons. The map served as theoretical framework that provided inferences 
about aptamer similarities. Aptamers that were selected against the same target were 





Figure 2.6. Global Distribution of RNA Aptamers in the Aptamer Database. A 
BLAST analysis of the RNA aptamer sequences in the database shows that aptamers that 
are isolated from the selections towards the same target were more closely related to each 
other than those selected against other targets. To construct this map, the aptamer 
sequences were compared each other using the BLAST software using default settings. A 
vertex represents one aptamer and a significant blast value is represented by an edge 
connecting the vertices. To reduce the multidimensionality of the BLAST relationships, 
an algorithm previously described by the Marcotte group is used [37].  
 
SEQUENCE INFORMATION ANALYSIS 
 
Given that aptamers and unnatural ribozymes were derived from random 
sequence libraries, we wanted to investigate whether functional sequences shared any 
qualities to random sequences and study the properties that constitute a functional 
sequence.  This question is more than just academic, in that a bias in sequence 
composition or function could help to inform genomic searches for natural, functional 




Figure 2.7 .  Sequence analyses based on the Aptamer Database. The random regions 
of all RNA aptamer and ribozyme sequences from the Aptamer Database were extracted, 
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and aggregate base compositions were determined.  White bars represent the nucleotide 
frequencies calculated for RNA aptamers.  Black bars represent the nucleotide 
frequencies calculated for ribozymes.  The individual residues (A, G, C, or U) are shown 
on the X-axis, while the Y-axis represents the frequency of each residue [34]. 
 
In this regard, in collaboration with the Professor Lauren Meyers, a base composition 
analysis of all of the sequences from the database reveals that there is a slight statistical 
skewing towards G and C (p-value < 0.01) in the base compositions of RNA aptamers 
and ribozymes relative to completely random sequences (equimolar A,C,G, and U; 
Figure 2.7).  
 As Schultes et al. [41] have previously observed, functional sequences, whether 
natural or unnatural, appear to have a slight preponderance of guanosine and cytidine.  
Interestingly, while the content of (G+C) appears to be similar for aptamers and 
ribozymes, ribozymes contain proportionately more U (and less A) than aptamers (p-
value < 0.01).  Beyond demonstrating that functional nucleic acid sequences of all sorts 
have particular sequence characteristics, these broad sequence analyses may inform the 
design of random sequence pools for selections; for example, it may be useful to skew the 
composition of a pool for the selection of ribozymes to a G:A:U:C ratio of 
0.28:0.22:0.24:0.26.  Since many selected ribozymes differ in sequence and function and 
cannot be aligned, this sort of analysis could be made much easier with the Aptamer 
Database. 
The collected availability of sequences in the database also facilitates other global 
analyses.  For example, we exported all of the RNA aptamer and ribozyme sequences and 
analyzed their potential for forming secondary structures using the program RNAfold 
from the Vienna RNA package [42].  The minimum free energy algorithm in RNAfold is 
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based on the dynamic programming algorithm developed by Zuker, et al. [43].  The 
Zuker algorithm only generates minimum free energy structures.  Another alternative 
would have been to look at the ensemble of lowest energy structures.  Lawrence and his 
co-workers conducted a study that compared the reliability of different RNA structure 
prediction algorithms [44].  Probability models that generate ensembles, such as 
McCaskill’s algorithm [45], did prove to be a better predictor of the structures of longer 
sequences.  However, for shorter (< 120 nucleotides) sequences, the improvements in 
structure prediction were modest and could primarily be attributed to the inability of the 
Zuker algorithm to take into account pseudoknots, a motif that is generally difficult to 
predict for any algorithm.  In the end, the comparative analysis [46] confirmed that the 
Zuker minimum free energy method was very reliable for structure prediction.  This 
method should be particularly appropriate for obtaining a general overview of the 
structural characteristics of the short selected sequences found in the database. 
The fraction of paired nucleotides in folded aptamer and ribozyme structures were 
analyzed and assessed to see whether they were significantly different from the fraction 
of paired nucleotides in folded randomized structures.  In this instance, the fraction of 
base pairs found in selected aptamer and ribozyme sequences is statistically greater than 
the fraction found in randomized versions of the same sequences as shown in Figure 
2.9A (p-value < 0.01). In addition, in selected sequences, G:C pairings are more abundant 
than  the A:U or G:U pairings, as shown in Figure 2.9B (p-value < 0.01). The large 
excess of G:C pairings is not a result of the only slightly higher concentrations of G and 
C in selected nucleic acids.  Taken together, these results reveal that selection for binding 
or catalytic function of necessity results in selection for secondary structural stability.  
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Schultes et al. [41]  have also shown that there is a preponderance of G:C pairings in the 
stem regions of natural, functional RNA molecules relative to unpaired regions such as 
loops. Similarly, examinations of natural sequences have suggested that G:C pairings are 
required to stabilize and present protein-binding sites [47-49]. 
 
 
Figure 2.8A. Base-pairing in selected sequences.  Overall base-pairing in RNA 
aptamers and ribozymes sequences. The fractions of base-paired residues were 
determined for RNA aptamers (white bar) or ribozymes (black bar). To determine 
whether the number of base-pairs that were formed was significantly influenced by 
selection, the random regions were randomized and re-folded for the RNA aptamers and 





Figure 2.8B. Distribution of Individual Base Parings. The data from Figure 2A was 
re-tabulated in terms of the types of base-pairs formed [34]. The white bar represents 
RNA aptamer sequences, and the black bar represents ribozymes sequences. The Y-axis 
represents the fraction of base-pairs in each class, normalized to the total number of base-
pairings found in Figure 2A. 
 
 
ROBUSTNESS OF SECONDARY STRUCTURES 
 
More complex analysis has been conducted based on the data acquired from the 
Aptamer Database. In collaboration with Dr. Lauren Meyers and Matt Copperthwaite, an 
analysis comparing the robustness of natural and unnatural secondary structures was 
carried out [50]. The premise of this analysis is that sequences of functional molecules 
have more stable secondary structures than random sequences. The question was whether 
this theory holds with equal importance for both artificially and naturally occurring 
molecules. Over 1000 evolved molecules were compared using two levels of structural 
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resolution: (i) The coarse-grained model, which uses the positions of structural 
components such as hairpins, stacks, or multiloops; and (ii) the standard secondary 
structure model that takes into account every nucleotide pairing position. 
 
Figure 2.9. Comparative Thermostability of Artificially and Naturally Evolved 
Molecules. Average percentile thermostability for artificial molecules (aptmers) and 
natural molecules (nonhuman eukaryotic tRNA; human tRNA; archaebacterial 5S rRNA; 
eubacterial 5S rRNA; eukaryotic 5S rRNA; natural hammerhead ribozymes). We use the 
Boltzman coefficient of the minimum free energy shape to estimate thermostability. The 
percentile is the rank of a sequence’s thermostability compared to the thermostabilities of 
1000 randomly generated sequences of the same length and base composition. Percentiles 
significantly above 0.5 are more thermostable than expected from a random sequence.  
 
 Figure 2.9 [50] shows that the thermodynamic stability of those naturally 
occurring molecules are higher than those of artificially selected molecules (aptamers). 
The notion that directed evolution is comparable to natural evolution is challenged based 
on these results. The level of optimization of the structures is not comparable to that 
perfected from years of natural selection. A similar trend is shown when analysis of 
primary sequences is carried out in chapters 3 and 4. Further explanations about the 
potential reason as to for the more stable secondary structures not being selected are 





The sequence and structural comparisons that have been carried out were 
relatively simplistic, they justify the contention that nucleic acids selected in vitro possess 
attributes similar to those of sequences found in nature.  The Aptamer Database should 
continue to be a helpful source for such comparisons. For example, as new sequence or 
structural motifs are found, such as the well-characterized tetraloop sequences that have 
been found to stabilize natural RNA sequences [46, 51, 52], their prevalence and utility 
can be further confirmed by an unbiased search of the Aptamer Database. 
 
METHODS AND MATERIALS 
APTAMER DATABASE  
 
The current version of the Aptamer Database contains entries from 237 papers 
that describe the in vitro selection of aptamers, ribozymes, and deoxyribozymes. The 
database primarily contains catalysts that have been selected from completely random 
pools, as opposed to variants on known, natural ribozymes. Each entry is described by the 
following fields: Author (last name and first name of the authors of each publication); 
Title; Medline Accession Number (allowing a direct link to the Pubmed record); Target 
(name of the ligand that was used for selection); Target Type (currently classified into 
proteins, peptides, nucleic acids, organic molecules, inorganic molecules or other); 
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Journal (year, volume, issue, pages); DNA/RNA or Modified (indicates whether the 
initial nucleic acid pool used for the selection was ‘natural’ or contained modified 
nucleotides); Buffer Conditions; Template Description (describes the length of the 
random region); Template Sequence (describes the sequences of the terminal primer 
binding sites); Sequences (list of each aptamer or ribozyme sequence that was selected, 
not including the Template Sequence or constant region). The database is updated 
monthly. Data is entered manually into the database. Each sequence is entered twice and 
the two entries are compared to ensure accuracy. The Aptamer Database is publicly 
available through http://aptamer.icmb.utexas.edu. To facilitate data entry by other users, a 
template of the database is available for download at http://aptamer.icmb.utexas/submit. 
A database management system (DBMS) is necessary to set up and maintain the 
database.  Different DBMSs exist, but for relational databases MySQL and 
POSTGRESQL are the preferred DBMSs for their speed and ease of use.  Both are 
publicly available without licensing fees for educational institutions and have extensive 
technical support from the community. All the information in available in the database is 
store in a MySQL database server.  Information is provided as a text file and a Perl 
pipeline has a modular structure that fills the tables of the MySQL database.  
A Web Server is crucial for the database to be publicly accessible. A server that 
allows the generation of dynamic web pages and the ability to interpret and execute 
scripts is necessary.  Apache is a web server that is freely available with the required 
capabilities. Typically scripts written in Perl or PHP are used as the backend database 
interface language and they follow the same licensing as previously described. Software 
that will translate and display specific contents of the database to the Internet for public 
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use will be needed. Many popular web interface software are available.  The choice will 
be dependent on the complexity of the web page and the functionalities the developer is 
trying to attain. The database’s web interface is based on the PHP language, and manages 
all the incoming queries. All available publication was found using a keyword search in 
literature databases such as Pubmed, Scifinder, and Chemical Abstracts. 
GRAPHICAL REPRESENTATION 
 
To construct the Chaos Game Representation (CGR) of the database, all the 
sequences were extracted in text format and the nucleotide composition of each sequence 
was analyzed. Only the random regions of the aptamers were accounted for during this 
analysis. The analysis is based on the algorithm presented by the Fletcher group in 2001 
[36].  In summary, the CGR space was generated by the aptamer sequences is a planar 
illustration confined by the four possible nucleotides as vertices of a binary square. 
To construct the map and space filled model of the database, we compared the 
nucleotide sequences with each other using the program BLASTN using default settings. 
The results of these were represented as a vertex in a network, and each significant 
BLAST similarity (E-scores of less than 10-9) was represented as an edge connecting the 
corresponding aptamers. The network was then converted to an undirected network by 
creating a single edge between two connected sequences and retaining the more 
significant of the two BLAST E-values as the weight. Once the coordinates of the layout 
were obtained, they are fed into LGL, which is an algorithm introduced by the Marcotte 
group used to visualize very large biological networks [37].  
37 
LGL is useful for visualizing the results nucleic acid sequence comparisons, made 
using the program BLAST. The results are interpreted as a large biological network, 
where each aptamer is represented as a vertex, and each significant BLAST similarity is 
represented as an edge connecting the vertices. This general approach is known to 
effectively identify both close and distant sequence homologs. 
SEQUENCE INFORMATION ANALYSIS 
 
The base composition analysis is carried out using a Perl script that would count 
the number of each nucleotide frequency for aptamer and ribozymes.  Secondary 
structures of the random regions of RNA aptamer and ribozyme sequences were obtained 
using the program RNAfold, implemented in the Vienna RNA Package [42].  The 
minimum free energy algorithm was based on the dynamic programming algorithm 
developed by Zuker et al. [43].  The fractions of base-paired residues were determined for 
RNA aptamers (white bar) or ribozymes (black bar).  The base-pair fractions for all 
individual aptamers or all individual ribozymes were averaged; the error bars provide an 
indication of the spread of these values.  To determine whether the number of base-pairs 
that were formed was significantly influenced by selection, the random regions were 
randomized and re-folded for the RNA aptamers and ribozymes.  
MEASURING THERMODYNAMIC STABILITY 
 
We computationally estimated the extent to which single molecules are buffered 
against thermodynamic noise. First, we computed the repertoire of structures that are 
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accessible to a sequence and approximated the probability of each structure. We used an 
extension of the standard thermodynamic minimum free energy folding algorithm, which 
permits the computation of all secondary structures within some energy range above the 
minimum free energy [42]. This algorithm provides reasonable approximations but is by 
no means perfect. It does not predict pseudoknots or other tertiary interactions, which are 
known to occur in both natural and artificial RNA molecules. The parameters are 
estimated at the physiological temperature of 37 C, which is appropriate for prediction of 
natural sequences. Artificial RNAs, however, are often selected and optimized at a lower 
temperature (25 C). These algorithms may thus make less accurate predictions for 
artificially selected molecules. Despite these limitations, we used the suboptimal folding 
algorithm to rapidly approximate the low energy portion of the secondary structure space 
of a given sequence. We neglected energy barriers and assumed that a sequence 
equilibrates among all structures whose free energy is within 5 kT of the groundstate. The 
5-kT choice amounts to approximately 3 kcal at 37 C and corresponds to the loss of two 
CG/GC stacking interactions. Under thermodynamic equilibration, we assumed that the 
Boltzmann probability of a shape S, exp(-!Gs/kT)/Z, approximates the overall fraction of 
time that the molecule spends in s, where !Gs is the free energy of structure S, k is the 
Boltzmann constant, T the absolute temperature, and Z = "exp ( -!Gs=kT)  is the 
partition function, which is computed by an algorithm previously described [45]. We 
used the Boltzmann probability of the lowest free energy state (the groundstate) to 
estimate the thermodynamic stability of a molecule. Thus we did not use minimum free 
energy alone to estimate thermostability but, instead, considered the extent to which a 
groundstate is stabilized with respect to competing shapes. In measuring thermodynamic 
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stability, we assayed secondary structures at two levels of resolution. The coarse grained 
secondary structure of a molecule notes the relative position of the following structural 
components: hairpins (H), interior loops (I), bulges (B), multiloops (M), and stacks (S). 
We first predicted the standard structure of a molecule, and then parsed the standard 
representation into these five components. When several suboptimal standard shapes 
reduced the same coarse-grained shape, we grouped them together and summed their 
Boltzmann coefficients. The coarse grained groundstate was the shape with the largest 
(collective) Boltzmann, which may or may not have corresponded with the original 
standard groundstate. In essence, the standard secondary structure looks at the precise 
sequence and structure of a molecule, while the coarse-grained structure is a measure of 
the overall fold, independent of sequence. By examining coarse-grained structures, we 
grouped structurally similar molecules. This may be appropriate, for example, if two 
nucleic acids are functionally similar because of a shared stacked helical junction, but 
these junctions in the two molecules differ in the number of single-stranded residues 
separating the two participating helices. Such molecules would be substantially different 
in the standard representation but appropriately equivalent in the coarse-grained 
representation. Coarse-grained structures also allow for some degree of error in the 
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CHAPTER 3: HIGH THROUGHPUT IN VITRO SELECTIONS OF 
APTAMERS 
INTRODUCTION 
ROLE OF AUTOMATION IN APTAMER SELECTIONS 
 
Experimental procedures using automation systems have become widely accepted 
in modern science. With the increasing need to generate vast amounts of data for the 
fields of genomics and combinatorial chemistry, it almost intractable to produce such 
amounts of data with the conventional bench science.  The improvements in this area 
have given way to robotically conducted experimental procedures to take over the 
repetitive practices of different experimental methods such as amplification reactions 
(PCR), sequencing reactions, microarray printing to name a few [1-3].  The integration of 
automation systems has eased the implementation of large-scale projects. Few examples 
of successful projects completed using robotic systems include the sequencing of the 
human genome, the mass spectroscopy analysis for protein-ligand interactions, and 
mammalian cell-line preparation [4-7].  
It is not abnormal nowadays to see conventional biological labs equipped with 
robotic platforms to undertake tedious and repetitive tasks, which in turn frees up the end 
user with more time to conduct the complex experimental tasks and data analysis. The 
degree of automated implementation has become so advanced that the King group has 
designed robotic systems that are able to devise and test hypothesis and continually 
refined the experiments to meet the hypothesis [3]. An important advantage of automated 
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platforms is the consistency of the experimental procedures. This fact ensures that 
variations in the outcomes of certain procedures are indeed due to the nature of the 
reaction and not because of the manual manipulations by different scientists. Precision 
and consistency is highly sought after for scientific experiments.  It is difficult to assess 
the results of in vitro selections when they are carried out manually since one cannot be 
sure whether the outcomes are due to discrepancies during the execution of the 
experiment.  Since in vitro selections involve such a large amount of varied steps, robotic 
selections ensures the analysis of the results with higher confidence due to the 
reproducibility benchmarks that automation platforms provide. Previous students in the 
Ellington lab, Colin Cox and Letha Sooter have both perfected the in vitro selection 
processes to robotic platforms with a high degree of success [8-11]. 
EXISTING AUTOMATED SELECTIONS 
 
While most of the selection protocols on robotics have been based on RNA pools 
[8-10], selections using ssDNA and dsDNA pools have been demonstrated as well [11]. 
Moreover, automated selections have been carried out within the lab using modified 
nucleotide pools.  Translating in vitro selections to robotic systems, many steps in bench 
selections are omitted during automated selections. These steps include PAGE nucleic 
acid purifications; instead the focus went on to ensure efficient amplification chemistry 
by maximizing the generation of binding species and minimizing the generation of other 
products such as primer dimers or parasites. Selections to date have been single target 
selections with one pool, or selections of multiple different targets conducted 
simultaneously on the platform, or selections against multiple targets with different 
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nucleic acids pool with different primer sets. No simultaneous selections against the same 
target with the same nucleic acid pool have been conducted. The reason for this fact can 
be attributed to the challenge at eliminating contamination. Robotic platforms are open to 
their local environment.  Encasements are available for some automations platforms; 
however, they are costly and a challenge in of itself to encase the platform that has third 
party hardware incorporated.  
CHALLENGES OF AUTOMATED SELECTIONS 
 
When I first embarked on performing automated selections, along with a former 
undergraduate student Travis Bayer, we observed that a certain degree of contamination 
occurred when selections were conducted in parallel when nucleic acids pools with the 
same primer binding regions were used. It appeared that the proximity of targets within a 
96-well plate was enough for amplicons to contaminate neighboring wells. It was obvious 
that further modifications would be needed to overcome this problem. This would require 
a highly systematic approach to narrow the potential areas of contamination that can 
occur during the process of selection on an automated platform. For those who are 
interested in selecting against different targets or use different nucleic acid pools, this 
might seem like a minor problem. But for complex questions concerning evolutionary 
theories, this can certainly undermine the results of data collected. I have undertaken the 
task to assess whether contamination issues arise when parallel selections that are 
conducted with different pools that contain identical primer binding regions and selected 
against the same protein target. The significance of this investigation is to further give 
credibility to automation, especially when selections against very similar targets are to be 
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conducted simultaneously.  
RESULTS AND DISCUSSION 
NEW HOUSEKEEPING PROTOCOL 
One of the main protocols that has been introduced into automated selections is 
the manipulating the initial pool in a “Round 0” hood free of contamination. The 
manipulation of every newly synthesized pool is confined inside the hood. Before and 
after each use, the hood is wiped down with bleach and “DNAse” Zap solution and 
“RNAse” Zap solution (Applied biosystems, Foster City, CA). In addition, after the hood 
is cleaned, UV radiation is used to further clean the surfaces. Except for UV radiation, 
robotic surfaces are meticulously wiped down with the same solutions. 
Another great contributor to the contamination is the thermalcycler due to the lack 
of cover for the 96 well plate. We tested different sealing pads for the thermalcycler lid 
until we found an MJ “P” that allows an airtight sealing of the lid to the PCR plate so that 
during amplification no amplicons are able to escape the wells. The amplification steps 
have also been modified so that the last step of the process involving the temperature to 
equilibrate to room temperature for 10 minutes to reduce evaporation when the 
thermalcycler lid is opened. 
INDIVIDUAL POOL AMPLIFICATION 
 
Before any action was taken to amplify an intact pool, which contains 
approximately 1x10
15
 unique nucleic acid sequence, it was split into 8 different aliquots 
each containing approximately 1x10
14
 unique molecules to each aliquot. Calculating the 
probability of finding a sequence in a pool of sequences requires two pieces of information: 
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the probability of finding the sequence in a single attempt, and the number of attempts to 
find it. For a sequence with a random region of length n=40 where each position has 25% 
of containing A, G, T, or C; the probability of finding a certain sequence is:  
P(sequence) = (1/4)40  = 8.3E-25 
The probability of finding this sequence twice is P2.= 6.8E-49. Each aliquot is individually 
large-scale amplified and transcribed into RNA. Eighteen rounds of selections were 
performed for the 8 pools against the protein target hen egg-white lysozyme 
simultaneously and analyzed as shown in Figure 3.1. 
 
 
Figure 3.1.  Initial Preparation of Newly Synthesized Pool. The newly synthesized  
“virgin” pool is subdivided into 8 different aliquots before amplification steps have taken 
place. This ensures that each aliquot will be exclusive distinct from each other. 
 
  
I started my selections with a newly synthesized N30 random sequence pool that 
was previously designed by former students Colin Cox and optimized by Sulay Jhaveri 
from the laboratory. The N30 pool contains a random region flanked by two constant 
regions. Figure 3.2 depicts the N30 pool design. 
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Figure 3.2. N30 Pool Representation. The bases that subsequently transcribed into RNA 
are shown as capitalized letters. Primer binding sequences are shown in lower case 
letters. The 5’ prier 41.30 incorporates a T7 promoter “gataatacgactcactata.“ This pool 
has been previously designed to contain restriction endonuclease recognition sites, which 
are underlined. 
 
The N30 pool’s dynamics are very well known, and multiple selections have been 
conducted in the Ellington Laboratory using this pool [9, 10]. However, due to the 
widespread use of such pool for in vitro selections both at the bench and on robotic 
platforms, there was a high degree of a dominant contaminant, an aptamer clone that was 
previously selected against the same target Lysozyme [8].  
To overcome the contamination issue, a second pool that was subsequently 
designed for selections contained a 40 nucleotide random as shown in Figure 3.3. I 
became the sole user of this pool and it has been solely used for robotic selections for the 
purpose of probing sequence space to ensure its integrity and to keep the lab-wide 
contamination to the minimum.  
 
 
Figure 3.3. Graphical Representation of the N40 random pool. Capitalized residues 
represent bases transcribed into the RNA pool; lowercase bases represent priming 
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sequences. The 42.40 primer incorporates a T7 RNA polymerase promoter 
(gataatacgactcactata). 
 
A single robotic run on the Biomek 2000 workstation performs six continuous 
rounds of aptamer selections in 18 hours.  The progress of each robotic run is assessed 
through the amplification of DNA and formation of RNA for each round of selection.  
This is observed by running 10% of the collected reactions from each amplification step 
for all 18 rounds of selection. The reactions of each aliquot are analyzed on a denaturing 
8% polyacrylamide gel to evaluate whether the RT-PCR reaction is successful in yielding 
dsDNA and whether the transcription (TXN) reactions produced RNA. This is an 
important step since robotic selections are continuous for 6 straight rounds, and there is 
no means by which the experimenter can control each step to make sure that every round 
is producing the nucleic acids needed for subsequent selections. For each pool, a total of 
3 robotic selections are conducted to acquire data equivalent to 18 round of selection. 
GLOBAL SELECTION ANALYSIS 
All 8 N40 random pools underwent 18 rounds of selection against lysozyme with 
each pool’s selection progress analyzed on an 8% polyacrylamide gel. Figure 3.4 shows 
the PAGE gel analyses of the dsDNA and RNA products generated for each round of 






Figure 3.4. Products Generated During the in vitro Selections of Pools 1-8. The figure 
shows the products that are isolated during the 18 round of selection against lysozyme. 
Each round of selection has one lane containing radiolabeled DNA from RT/PCR 
reactions, and another lane containing RNA transcribed products. The longer RT/PCR 
lane shows a product of 107 bases for the DNA template, while the shorter band in the 
transcription lane contains a product of 87 bases. A 10bp radiolabeled RNA ladder flanks 
the product lanes. 
 
POOL 1 ANALYSIS 
  
 The next step that I carried out was to analyze the affinity of the selected pool to 
the protein target through a nitrocellulose-binding assay. Not every round was assayed 
for binding, except for round 0 (unselected RNA), round 6, round 12, and round 18. For 
each assay carried out, the main control utilized is clone 1, which previously isolated and 
highly characterized aptamers isolated from the N30 pool against lysozyme [8]. Binding 
assays involve the incubation of radiolabeled aptamers from each round against the 
target. The reaction is allowed to take place at room temperature and then passed through 
a filter for nitrocellulose and nylon as depicted in Figure 3.5. 
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Figure 3.5. Nitrocellulose Binding Assays. Radiolabeled RNAs are incubated with the 
target of interest in selection buffer. After the incubation, the reaction is passed through 
two layers of filter, one nitrocellulose and the other nylon.  RNAs that are bound to the 
target will remain in the top later of nitrocellulose along with the protein while the non-
binders will flow through and remain in the nylon membrane. 
 
It is important to use an aptamer control with a known behavior because previous 
data showed that nitrocellulose membranes vary from badge to badge leading to 
variations in the results. Using a highly characterized aptamer clone, we can standardize 
the numerical data from the binding assay reactions. To further ensure the fidelity of the 
data, all nitrocellulose-binding assays are carried out in triplicates and at least twice on 
different occasions.  
 
Figure 3.6A illustrates the affinity trend of Pool 1 for free Lysozyme at different 
stages of the selections. Isolated RNAs were assayed against free Biotin to ensure that 
there was no nonspecific binding. The rationale for this step was to ensure that the 
winning species isolated were specific to the target and not to the biotin that has been 
conjugated to the protein target prior to the start of the selections. Pool affinity to the 
protein does not become obvious until selection round 12, which is expected of general 
selections. However, going from round 12 to round 18, there was a drop in binding 
affinity to the enzyme. There seemed to be a turnover of species going from round 12 to 
18. Looking at the individual sequences isolated from each tested round, at round 12; 
there was an accumulation of sequence families. These families completely disappeared 





Figure 3.6A. Affinity Trends of Pool 1 for Lysozyme.  RNA from different rounds 
were assayed and incubated with protein Lysozyme (+), incubated with only buffer (-), or 
with pure Biotin (B). Two different wash buffers were analyzed. Binding assays washed 
with a buffer identical to the selection buffer conditions is shown in red bars, and a high 
salt buffer wash containing 3X more salt (Sodium Chloride NaCl) than the selection 
buffer is shown in blue bars. 
 
 Looking at the isolated sequences from Pool 1 selections, the binding trend was 
translated into the sequences isolated (Figure 3.6B). From the binding data, it appears as 
though the pool at round 12 is slowly showing an improved binding, however, binding 
drops to almost background once it reaches round 18. At round 12 a predominant family 
was forming (A-3) among others, however, these binders disappeared at round 18. Not 
only did some of the sequences disappear, round 18 seems became more complex. 
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Figure 3.6B. Pool 1 Sequence Clones from Rounds 6, 12, and 18. N40 pool sequences 
 58 
isolated from Pool 1 selection. The primer binding regions are colored maroon. Random 
regions are in black. Random regions that are highlighted signify identical sequences. 
Many sequences that were becoming dominant within round 12 of the isolated sequences 
dropped out at round 18. The binding of the aptamers also dropped from round 12 to 18. 
 
A likely explanation for this observation is there may be a depletion of the good 
binders during the selection from round 12 to round 18. In vitro selection experiments are 
dependent on the amplification of functional species, and structural stability will 
discriminate between amplicons based on this trait rather than its ability to bind to the 
target. Stable RNA secondary structures that makes it difficult for the sequence to reach 
attain the conformation making it harder for polymerases to reach [12, 13]. An example 
of this is evidenced during in vitro selection of an RNA ligase. In this selection, RNA 
species with inactive conformations were isolated potentially because replication was 
more effective with conformational flexibility [14]. In another example, a selection for 
oligonucleotide targets for the T4 DNA ligase yielded mismatched species to the template 
because perfectly paired substrates were not as efficient during the amplification step 
[15].  
POOL 2 ANALYSIS 
 
 Affinity trends for that of Pool 2 shows a gradual increase in the fraction of 
nucleic acids bound going from round 0 to round 12. No significant increases in binding 




Figure 3.7A. Affinity Trends of Pool 2 for Lysozyme. RNA from different rounds were 
assayed and incubated with protein Lysozyme (+), incubated with only buffer (-), or with 
pure Biotin (B). Two different wash buffers were analyzed. Binding assays washed with 
a buffer identical to the selection buffer conditions is shown in red bars, and a high salt 
buffer wash containing 3X more NaCl than the selection buffer is shown in blue bars. 
 
By looking at the sequences isolated from the assayed rounds (Figure 3.7B), after 
18 rounds of selection, the pool was still highly complex without any predominant 
winning species. It could be inferred that these sequences were not evolving towards a 
region of better functionality. Traditionally during manual in vitro selections, one can 
increase the stringency so that the better binders and winnow down the pool size.  
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Figure 3.7B. Pool 2 Sequence Clones from Rounds 6, 12, and 18. N40 pool sequences 
isolated from Pool 1 selection. The primer binding regions are colored maroon. Random 
regions are in black. Random regions that are highlighted signify identical sequences. In 
this pool, there is no sign of pool enrichment in the different rounds of selection. In 
traditional selection methods, this result usually signifies that the selection has not gone 
to completion and additional manipulations, such as increasing in stringency, are needed 
to enrich the pool for better binders. 
POOL 3 ANALYSIS 
The binding data for Pool 3, more than two fold improvement in pool binding 
occured from round 12 to round 18 (Figure 3.8A). Evaluating the dynamics of pool 3 in 
terms of isolated clones from the selection (Figure 3.8B), it became clear that this 
increase in binding trend is expected. The round 12 pool was already highly enriched 
with one species of sequence populating half of the pool. At round 18, one predominant 
sequence clone overtook the entire pool. This is the general trend that is often observed in 




Figure 3.8A.  Affinity Trends of Pool 3 for Lysozyme. RNA from different rounds 
were assayed and incubated with protein Lysozyme (+), incubated with only buffer (-), or 
with pure Biotin (B). Two different wash buffers were analyzed. Binding assays washed 
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with a buffer identical to the selection buffer conditions is shown in red bars, and a high 




Figure 3.8B. Pool 3 Sequence Clones from Rounds 6, 12, and 18. N40 pool sequences 
isolated from Pool 1 selection. The primer binding regions are colored maroon. Random 
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regions are in black. Random regions that are highlighted signify identical sequences. 
Underlined sequences show common motifs among the aptamer clones 
POOL 4 ANALYSIS 
 
Looking at the pools affinity towards the target Lysozyme, Pool 4 behaved in the 
same fashion as Pool 2 as shown Figure 3.9A.  The pool did not seem to evolve at a great 
degree with binding only slightly better than the unselected pool, and no drastic change 
occurred from round 12 to round 18. 
 
 
Figure 3.9A. Affinity Trends of Pool 4 for Lysozyme. RNA from different rounds were 
assayed and incubated with protein Lysozyme (+), incubated with only buffer (-), or with 
pure Biotin (B). Two different wash buffers were analyzed. Binding assays washed with 
a buffer identical to the selection buffer conditions is shown in red bars, and a high salt 
buffer wash containing 3X more NaCl than the selection buffer is shown in blue bars.  
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Figure 3.9B. Pool 4 Sequence Clones from Rounds 6, 12, and 18. N40 pool sequences 
isolated from Pool 1 selection. The primer binding regions are colored maroon. Random 
regions are in black. Random regions that are highlighted signify identical sequences. 
Underlined sequences show common motifs among the aptamer clones. 
POOL 5 ANALYSIS 
 
The binding assay for Pool 5 shows that the isolated pools’ affinity to Lysozyme 
is much higher (fractions higher than 0.15 as opposed to 0.10) as shown in Figure 3.10A. 
The improvement in binding followed a gradual trend. Moreover, the affinity was 
improved to about 0.25, a significant improvement. This trend signals the reduction in 
pool complexity to a few strong binders [8, 9, 16, 17]. 
 
Figure 3.10A. Affinity Trends of Pool 5 for Lysozyme. RNA from different rounds 
were assayed and incubated with protein Lysozyme (+), incubated with only buffer (-), or 
with pure Biotin (B). Two different wash buffers were analyzed. Binding assays washed 
with a buffer identical to the selection buffer conditions is shown in red bars, and a high 
salt buffer wash containing 3X more NaCl than the selection buffer is shown in blue bars. 
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 From the sequences isolated, there was no predominant clone that was found in 
the pool, however, a distinctive GC rich motif towards the 3’ end of the random region 
was observed across all round 18 sequences. (Figure 3.10B) 
 
 
Figure 3.10B. Pool 5 Sequence Clones from Rounds 6, 12, and 18. N40 pool 
sequences isolated from Pool 1 selection. The primer binding regions are colored maroon. 
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Random regions are in black. Random regions that are highlighted signify identical 
sequences. Underlined sequences show common motifs among the aptamer clones. 
POOL 6 ANALYSIS 
This pool’s binding trend showed a lot of parallel to that shown for Pool 3 
(Figure 3.11A). The ability of the pool to bind to the target at round 18 was high. This 
can only be explained by the loss of pool complexity at this stage with the presence of 




Figure 3.11A. Affinity Trends of Pool 2 for Lysozyme. RNA from different rounds 
were assayed and incubated with protein Lysozyme (+), incubated with only buffer (-), or 
with pure Biotin (B). Two different wash buffers were analyzed. Binding assays washed 
with a buffer identical to the selection buffer conditions is shown in red bars, and a high 
salt buffer wash containing 3X more NaCl than the selection buffer is shown in blue bars. 
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Figure 3.11B. Pool 6 Sequence Clones from Rounds 6, 12, and 18. N40 pool 
sequences isolated from Pool 1 selection. The primer binding regions are colored maroon. 
Random regions are in black. Random regions that are highlighted signify identical 
sequences. Underlined sequences show common motifs among the aptamer clones. 
POOL 7 ANALYSIS 
The binding for this pool shows similar trend as that of Pool 1-3, just at a much 
higher affinity (closer to 0.2 as opposed to 0.1) (Figure 3.12A). As it can be predicted 





Figure 3.12A. Affinity Trends of Pool 7 for Lysozyme. RNA from different rounds 
were assayed and incubated with protein Lysozyme (+), incubated with only buffer (-), or 
with pure Biotin (B). Two different wash buffers were analyzed. Binding assays washed 
with a buffer identical to the selection buffer conditions is shown in red bars, and a high 




Figure 3.12B. Pool 7 Sequence Clones from Rounds 6, 12, and 18. N40 pool 
sequences isolated from Pool 1 selection. The primer binding regions are colored maroon. 
Random regions are in black. Random regions that are highlighted signify identical 
sequences.. 
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POOL 8 ANALYSIS 
 
The binding trend, albeit with higher fraction bound, has a very similar look to 
that of Pool 4. The binding peaks at about 0.30 at round 12 and gets significantly reduced 
again at round 18 (Figure 3.13A). The binding trend strongly points towards an 
enrichment of favorable species. Figure 3.13B shows an enrichment of when the 
selection reached its completion at round 18. Different clones are starting to appear on 
multiple occasions. 
 
Figure 3.13A Affinity Trends of Pool 8 for Lysozyme. RNA from different rounds 
were assayed and incubated with protein Lysozyme (+), incubated with only buffer (-), or 
with pure Biotin (B). Two different wash buffers were analyzed. Binding assays washed 
with a buffer identical to the selection buffer conditions is shown in red bars, and a high 
salt buffer wash containing 3X more NaCl than the selection buffer is shown in blue bars. 
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Figure 3.13B. Pool 6 Sequence Clones from Rounds 6, 12, and 18. N40 pool 
sequences isolated from Pool 1 selection. The primer binding regions are colored maroon. 
Random regions are in black. Random regions that are highlighted signify identical 
sequences. Underlined sequences show common motifs among the aptamer clones. 
ASSESSING THE ABSENCE OF CONTAMINATION IN THE SELECTIONS 
 
Phylogenetic analysis of the round 18 sequences show that all 8 different pool 
aliquots have been selected successfully without cross contamination across the different 
pool aliquots during the selection process as shown in Figure 3.14. Identical sequences 
within the same pool aliquot were input only once into the analysis. The phylogenetic 
analysis shows that no two sequences from the different pools shared the same branch as 
it would be expected from identical sequences. The number of sequences was reduced in 
order to provide an intelligible graphical representation. Reducing cross contamination is 
one of the greatest challenges for automated selection. The lack of enclosure of the 
robotic platform makes contamination a likely event during the run. Thorough cleaning 
after each run and the use of filter systems that removes nucleic acids aerosols reduced 
this phenomenon.  The mechanism of robotic selections had to be modified in order to 




Figure 3.14. Phylogenetic Analysis of Round 18 Sequences. The phylogeny is 
constructed by comparing the hamming distance of the random region among the isolated 
aptamers and plotted using the DNAdist software from the PHYLIP software package 
[18]. The lack of overlap among the phylogenetically analyzed sequences indicates that 
there is no cross contamination among the 8 pools selected in parallel. The number of 
sequences used has been reduced in this graph. Previously isolated aptamers are 
incorporated into the analysis to show that no previously isolated aptamers have been 
isolated in the new selections. 
Conclusions 
A automated in vitro selection system capable of performing selections in by 
proceeding through six rounds of selection before fresh reagents are required (usually a 
18 – 20 hour period) has been designed in a modular format, utilizing as many off-the-
shelf components as possible so that we can quickly replace broken subsystems, or 
rapidly build new workstations. Despite the modularity of this system, it remains highly 
configurable, allowing a wide variety of selection conditions and procedures. As versatile 
as the system seems, the issue of cross contamination within the system can make it less 
than desirable to be used. With a few modifications, 8 pool parallel selections had been 
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carried out successfully. Not only were the problems resolved further validating the 
utility of the robotic platforms; it also opened many different areas of research that can be 
accessed with this technology.  
These selections were not only successful at addressing the contamination issue; it 
also gave us a glimpse at the degree of variation in the behavior of different pools when 
they contain different unique sequences. Based on the binding data, it can be inferred the 
extent of pool enrichment that has occurred during a round of selection. A question that 
arise from this experiment is that if there is such diversity when there is such difference 
in complexity is how efficient are in vitro selections at isolating the best binders? Many 
aspects such as effects of priming regions [19], type of selection buffer [20-25], length of 
pool, and target immobilization are known to how they can affect the outcome of 
selection. But the effect of different complexity of the pool has never been tapped into 
experimentally. Chapter 4 is devoted to analyzing the outcomes of the individual 
aptamers isolated from each pool and compared to one another.  
The aspect of theoretical biology and biological systems modeling on computer 
workstations might have seemed only limited to the field of bioinformatics. However, 
with the ability to generate such a vast amount of data in a short amount of time 
experimentally, studying evolutionary patterns is not far from reach. Chapter 4 is 
provides a glimpse at the extent that automated selection can be used to probe a small 
area of theoretical biology that was reserved to the selected few.  
THE FUTURE OF ROBOTICS 
Different students in the lab throughout the years have investigated adaptation of 
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this technology to a larger robotic worksurface in the past. Having the cross 
contamination issues addressed, the robot can be further outfitted to select very closely 
related targets. One of the main interests in the lab is to automate cell-surface selections. 
Most tumor mammalian cells possess highly similar surface properties; nixing cross 
contamination is critical for successful selections. I have currently worked out the 
particulars such as components that are needed for automated cell surface selections and 
a High School student Daniel Winkler is in the process of incorporating them into the 
Biomek 2000 and Tecan Genesis platforms. 
MATERIALS AND METHODS 
NEW SELECTION POOL DESIGN 
 
In traditional primer and pool design, it is commonplace to have ‘strong’ (S) 
bases, such as ---GGC towards the primer ends to increase priming efficiency [26]. An 
important trait of automation pools that makes them different from normal selection pools 
is that they have ‘weak’ (W) 3’ primer binding ends. An important feature of robotic 
selections is by-passing of PAGE purifications, and the uniform number of PCR cycles 
for numerous of rounds of selection, it is crucial to design a pool that is able to undergo 
an infinite number of amplification steps without the generation of parasites. Since 
amplification efficiency is one of the crucial aspects of automated selections, having a 
SWW 3’ primer ends that hybridize poorly will help this aspect without the generation of 
unwanted amplicons that can occur in ends that are characterized by WSS clamps [19].   
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POOL SYNTHESIS AND PURIFICATION 
 
One !mole syntheses of pool template strand and primers were synthesized on an 
Expedite DNA synthesizer (Applied Biosystems, Foster City, CA). N40 pool (GGG AGC 
ATT GCC CAC TCA TTT TCA NNN NNN NNN NNN NNN NNN NNN NNN NNN 
NNN NNN NNN NNN N TCA CTA GTT CGC GTT GCT GAA); 42.40 (GAT AAT 
ACG ACT CAC TAT AGG GAG CAT TGC CCA CTC ATT TTC); 20.40 (TTC AGC 
AAC GCG AAC TAG TGA); where “N” represents the random region of the pool, 
where all four phosphoramidites are injected simultaneously. Because each base has a 
different coupling efficiency, the “N” mixture is prepared with A:C:G:T 
phosphoramidites ratios of 3:3:2:2.4, respectively [27]. The synthesized nucleic acid was 
deprotected by incubation of the synthesis resin in 1 ml of ammonia hydroxide at 50ºC 
for 16 hours. A 10x volume of n-butanol was added and oligos were allowed to 
precipitate at -20ºC overnight. The oligos were spun down, ethanol rinsed, and then gel 
purified on polyacrylamide gels. One-third of the pool syntheses were purified per each 
10 x 12 x 0.15 cm 8% acrylamide gel. One-half of the primer syntheses were purified per 
each 10 x 12 x 0.15 cm 12% acrylamide gel. After running the gels for approximately 
two hours at 250 V (until the bromophenol blue loading dye reaches the bottom of the 
gel), the nucleic acid was visualized by placing the gel on a thin-layer chromatography 
plate and UV shadowing [28].Visual bands containing the appropriate mass of nucleic 
acid were excised with a clean razor blade. Gel fragments were eluted in pure water, 
approximately 30 ml per 10 x 12 x 0.15 cm gel excision. After overnight elution at 37ºC 
on a rotator, the water nucleic acid mixture was ethanol precipitated with sodium acetate, 
and quantitated by UV spectroscopy. The purified N30 synthesis was determined to 
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contain a total of 2.44x1016 strands. 
N40 LIBRARY COMPLEXITY DETERMINATION 
 
During nucleic acid library synthesis, a substantial portion of the pool created by 
the synthesizer is not extendable my polymerases. Backbone lesions, incomplete de-
protection of the bases, and deletions are the artifacts that arise during synthesis affecting 
pool extension [27]. Pool extension assays are crucial for determining the complexity of 
the pool and for determining the fraction of the pool that is amplifiable with a 
polymerase. The assay involves the radiolabeling of 40 pmol of the pool primer (20.40) 
in 10 uL of kinase reaction with 5X forward polynucleotide kinase reaction buffer, "-32P 
ATP (>7,000 Ci/mmol) (ICN Biomedicals, Irvine, CA), and T4 polynucleotide kinase 
(Invitrogen, Carlsbad, CA). The reaction is incubated at 37ºC for 1 hour and 
phenol:cholorform extracted. The primers are separated from the organic phase using a 
PhaseLock tube (Eppendorf, Hamburg, Germany). The final step involves the removal of 
free nucleotides by size-exclusion chromatography with Centri-Spin 20 microcentrifuge 
columns (Princeton Separations, Adelphia, NJ). 
Both a DNA polymerase and a reverse transcriptase (RT) are used to test for pool 
extension.  RTs are more efficient at extending the pools because of its error-prone 
nature, meaning that they are able to overcome chemically modified or damaged base 
strands [29-31]. Taq DNA polymerase (Promega) and SuperScript III reverse 
transcriptase (Invitrogen) are the two enzymes to evaluate pool extension. For the RT 
reaction, it involves incubating an excess amount of the pool (50 pmol) with a limiting 
amount of the labeled primer (10 pmol) with 10 nmol of dNTPs and water in a 10 uL 
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reaction, heat denatured at 70ºC for 5 minutes and chilled. First strand buffer (4 uL), 
0.1M DTT (2 uL), 1 unit of RT enzyme, and water are added to bring the reaction to a 
final volume of 20 uL. The reaction is incubated at 42ºC for 1 hour. For the Taq DNA 
polymerase reaction, the radiolabeled primer is annealed to the ssDNA pool by adding 10 
pmol of the primer with 50 pmol of the purified pool. Additional 10 nmol of dNTPs and 
water added to bring the volume to 10 uL followed by a denaturing step at 70ºC for 5 
minutes and chilled. PCR buffer added to the chilled reaction along with 1 unit of the Taq 
enzyme. The reaction is incubated at 72ºC for 1 hour. Once both reactions are completed, 
5 uL aliquots of each reaction is added to an 5 uL of 2X stop dye and denatured at 70ºC 
for 3 minutes. The sample are then analyzed on an 8% PAGE gel and imaged (Figure 
3.15).  
 
Figure 3.15. Extension Analysis of Synthesized Pool. The ssDNA pool is analyzed for 
extension using radiolabeled primers. A DNA polymerase and Reverse Transcriptase and 
used and compared to each other. One column is the primer itself, the second column is 
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the primer incubated with the pool. 
POOL AMPLIFICATION FOR SELECTIONS 
Before each new pool can undergo selections, a small scale PCR is crucial to 
optimize the reaction conditions. These are needed to ensure that the new pools are not 
over-amplified, which is a critical aspect of successful selections [27].  Small-scale 
reactions are almost a mirror image of the large-scale reactions carried out in PCR thin 
well microplates (Bio-Rad Laboratories, Hercules, CA). The initial amount of template 
required to start a reaction follows the assumption that a traditional 100 uL PCR reaction 
will yield at most 1 ug of products. The initial goal is to obtain 10 copies of each viable 
nucleic acid sequence and my starting condition for each pool is 1x10
14
 unique viable 
fully extendable sequences from the synthesis. The mass of 1 double-stranded copy of 
10
14
 molecules is 1.2x10
-5
 g; hence for 10 double stranded copies of the N40 DNA will 
be 1.2x10
-4
 g. If each PCR reaction would yield 1 ug of product, to obtain the mass for 10 
copies would require 12 mL of PCR reaction (120 reactions of 100 uL). Since for each 
pool that is going to be tested has 1x10
14
 unique sequence in 100 uL volume, each small-
scale PCR reaction will contain 0.83 uL of the ssDNA template, 4 pmol of each primer 
(20.40 and 42.40) and 20 nmol of dNTPs. Once the PCR conditions are optimized, the 
large-scale amplification of the ssDNA pools can take place to generate the library 
necessary to initiate the selections. 
For the purpose of this study, extreme caution had to be conducted to avoid cross-
contamination across the 8 different pools. Once the newly synthesized pool has been 
divided into 8 aliquots single aliquots, in no time during the small-scale or large-scale 
PCR amplification have any two aliquots been worked on at the same time. During this 
sensitive time, each pool was worked individually under a hood that is that is cleaned 
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with bleach, RNAse Zap solution (Applied Biosystems, Foster City, CA), and ethanol 
before and after each manipulation of the pool. This is to ensure the integrity of the pool.  
Once the each aliquot is PCR amplified, all the reactions are pooled and ethanol 
precipitated with 0.3 M of sodium acetate. The DNA pellets are then suspended in water 
and checked for integrity on a 4% agarose gel.  Once the dsDNA copies are obtained, 
they will be transcribed into the RNA form. Large-scale transcriptions are conducted for 
each pool separately. The 1 mL transcription reactions include 7.5 mM of each nucleotide 
(ATP, CTP, GTP and UTP), 10 mM of DTT, 1X T7 transcription buffer obtained from 
AmpliScribe kits (Epicentre, Madison, WI) and the dsDNA previously amplified. The 
reactions are incubated at 42ºC for 4 hours. All traces of DNA in the transcription is 
removed by the addition of DNase I and incubated at 37ºC for an additional hour. The 
RNA is purified on an 8% PAGE gel, eluted and ethanol precipitated.  
 
TARGET PREPARATION 
Lysozyme purified from hen egg white was purchased from Sigma-Aldrich (St. 
Louis, MO). The enzyme was suspended at a 1 mg/mL concentration in the selection 
buffer (see below), and chemically biotinylated using sulfo-NHS-LC-biotin (Pierce, 
Rockford, IL). The biotinylation reaction occurred at a 10# molar ratio of biotinylating 
reagent to enzyme, and proceeded for 2 h on ice. Unincorporated biotin was removed via 
a 10DG chromatography desalting column (Bio-Rad, Hercules, CA). The biotinylated 





Figure 3.16A [32]. Image of the Selection System Used for Selections. The system is 
outfitted with a thermalcycler  with an automated lid integrated and controlled through 
the computer system that runs the robot. An enzyme cooler allows the enzymes to remain 
active for over 18 hours. The carousel functions to feed the system with new pipet tips. 
 
The selections are carried out on a Biomek 2000 Laboratory Automation 
Workstation (Beckman Coulter, Fullerton, CA) a shown in Figure 3.16A [32]. The robot 
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is integrated with a PTC-200 thermal cycler (MJ Research, Waltham, MA), a multiscreen 
vacuum filtration manifold (Millipore, Bedford, MA), and an enzyme cooler engineered 
in the laboratory by Tim Riedel. A Stacker Carousel (Beckman Coulter) feeds fresh 
pipette tips to the workstation as needed. Figure 3.16B [32] is a diagram of the 
worksurface and the placement of the plates that play a role in the selection process. A 
unique aspect of the N40 selection is the integration of a plate shaker in the location of 
the target plate. Since the magnetic beads tend to cement to the bottom of the plate, a 
shaking motion keeps the beads mobile thus reducing the necessity of constantly pipette 
just to keep the mixture well mixed. Pipetting constantly may cause the attachments of 
the beads and targets to the tips, which can lead to potential loss of RNA binding species. 
Figure 3.16B [32]. Schematic of Biomek 2000 worksurface. The relative positions of 




Colin Cox and Letha Sooterhad had previously designed the mechanical 
manipulations involved in Biomek 2000 protein selections [10]. In summary, the 
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principal differences between manual and automated selections are the protein target 
preparation. In automated selections targets are initially biotinylated and subsequently 
conjugated to magnetic beads after initial incubation of the nucleic acid pool and the 
protein target. The basic steps is illustrated in Figure 3.17 [8]. The modification involved 
in the N40 selections is the first incubation step. Instead of introducing the nucleic acid 
pool to biotinylated targets conjugated to beads, they are introduced to biotinylated 
targets prior to their conjugation to streptavidin coated magnetic beads. The rationale for 
this step is to reduce the non-specific binding of nucleic acids to the beads. The eight 
RNA pools are carried through 18 rounds of in vitro selection simultaneously against the 
hen egg white Lysozyme using the Beckman Biomek 2000 workstation. In the first round 
of selection, the amount of RNA of each pool applied is 5 ug (ca. 1.1x10
14
 sequences). 
Thereafter, approximately one-fifth of the preceding RNA transcription reaction is 
applied to the solution of biotin-lysozyme to begin the next round of selection.  
The very first step of the selection involves incubating the RNA with the 
biotinylated lysozyme in selection buffer (20mM Tris (pH 7.5), 100mM NaCl, 5mM 
MgCl2).  Streptavidin-derivatized Dynabeads (Dynal Biotech, Brown Deer, WI) are used 
to ‘rescue’ or conjugate the biotin-lysozyme and any bound RNA.  The bead, target, and 
RNA mixture is then filtered through a Millipore HV (PVDF) filter on a vacuum 
manifold to partition the lysozyme binding RNA from the unbound RNA. The winning 
RNA species are eluted from the target through a temperature denaturing step and then 
amplified through a reverse transcription coupled PCR (RT–PCR) reaction followed by a 
transcription reaction.  The RT–PCR reaction buffer contains 10 mM Tris (pH 8.4), 50 
mM KCl, 1.5 mM MgCl2, 0.2 mM dNTPs, 5% acetamide, 0.05% Nonidet P40, and 0.5 
 85 
mM each of the primers). RT–PCR enzyme mixture contains 5 U of SuperScript III 
enzymes (Invitrogen), and 0.2 U of Display Taq (Display Systems, Vista, CA), 50% 
glycerol, 10 mM Tris (pH 8.4), 50 mM KCl, and 1.5 mM MgCl2. A fraction of the RT–
PCR mixture serves as template for the following transcription reaction to generate the 
enriched RNA species for the next round of selection. The transcription buffer has 40 
mM Tris (pH 7.9), 26 mM MgCl2, 5 mM dithiothreitol (DTT), and 2.5 mM of each NTP. 
The transcription enzyme mix contained 40 units of RNasin (Promega, Madison, WI) 
ribonuclease inhibitor and 100 U of T7 RNA polymerase (Stratagene, La Jolla, CA). The 
selection progress is evaluated at every round by adding $-32P radiolabeled ribo- and 
deoxyribonucleotides to the amplification reactions buffers and archiving small aliquots 
(10 uL) of the reactions to be resolved in 8% acrylamide denaturing gel. The gels are 
dried visualized using a PhosphorImager SI (Amersham Pharmacia Biotech).  
RNA POOL ASSAYS 
Individual pools were assayed for binding activity by incubating equimolar 
amounts of the isolated RNAs to Lysozyme in selection buffer. Nitrocellulose filter-
binding assays were employed to determine the fraction of aptamer bound to Lysozyme 
[33] using A minifold I filtration manifold (Schleicher and Schuell, Keene, NH). A 
sandwiched nitrocellulose (Protran from Schleider & Schuell) and nylon membrane 
(Hybond N+ from Amersham Pharmacia Biotech) is assembled in the modified minifold 
attached to a vacuum. The binding reactions are filtered through the assembled apparatus 
and washed with 300 uL of wash buffer. The amount of radiolabeled RNA captured on 
the nitrocellulose is quantitated using a PhosphorImager SI (Amersham Pharmacia 
 86 
Biotech). The fraction of RNA captured is calculated by the following equation: 
 
Fraction of RNA bound   =           RNA captured on nitrocellulose         . 
    RNA on nitrocellulose + RNA on nylon 
            
The assays for the different pools were carried out on the same day to reduce the 
amount of variation during sample manipulations. Clone 1 used in the assay was the 
previously selected lysozyme aptamer [8] serving as the positive control. RNA was also 
incubated with the Dynalbeads and assayed to ensure that the aptamers selected were not 
bead binders.  
 
Figure 3.17. Robotic Aptamers Selections Against Protein Targets [8]. This diagram 
depicts the steps that are involved in one single round of selection that takes place on the 
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Biomek 2000. The red dots represent the magnetic beads coated with streptavidin, which 
aids in the conjugation and capture of the biotinylated protein targets with nucleic acid 
binders. The initial steps involves the addition of the RNA pool to a protein target 
captured on magnetic beads followed by filtration washing of the beads, elution of 
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CHAPTER 4: PROBING APTAMER FITNESS LANDSCAPES WITH 




Fitness has very different meanings. In population genetics, fitness describes the 
ability of a genotype to survive from one generation to another. Some evolutionary 
biologists use fitness to describe phenotype adaptation to the environment [1]. Overall, 
fitness is subjective depending on the feature the end user is trying to test and describe.  
In our study, we define fitness as the ability of the aptamer to evolve its binding to the 
target lysozyme. 
The concept of adaptive walks on fitness landscapes has captivated evolutionary 
biologists ever since Sewall Wright introduced it in 1932 [2].  According to Wright, to 
improve fitness, a fitness peak must be reached within a population by “climbing” a 
landscape. For theoretical biologists, understanding the topography of the landscapes has 
been of great interest. An optimal system is defined as the ability of the system to arrive 
at a global maximum in a multidimensional fitness space, and finding this optimum is 
also known as a combinatorial optimization [3]. Since biological systems are considered 
to be highly complex, it is assumed that their fitness landscapes are often extremely 
rugged, especially when their parameter involves their genotype or sequence space [4]. 
The phenotype of a system dictates its viability and fitness landscapes are a 
representation of this property on sequence space. Hence fitness is a multidimensional 
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function of sequence space.  
The nature of the landscape that correlates molecular sequence to molecular 
function has been the focus of a number of evolutionary theorists. These theoretical 
studies have primarily been modeled in silico due to the vast amounts of data needed that 
were deemed unattainable through the traditional wet-lab approach.  Theoretical 
biologists have for many years speculated on the nature of fitness landscapes, such as 
how sequence space maps to any of a number of different phenotypes (including folding, 
catalysis, and substrate specificity).  For example, Schuster and his co-workers have used 
in silico models to exhaustively examine how nucleic acid sequences map to particular 
secondary structures [5, 6].  These authors have come to several remarkable conclusions, 
including the notion that most available secondary structures can be found in a relatively 
small subset of sequence space.  It is therefore not necessary to explore the entire 
sequence space to attain the best (or evolutionarily successful) structure. Such findings 
have important implications and may be tested experimentally. 
ROLES OF IN VITRO EVOLUTION AND SEQUENCE SPACE ANALYSIS 
 
With the advent of selection and amplification techniques, conducting directed 
evolution provides detailed insight into the dynamics of evolving in vitro systems. For 
example, the information that can be obtained from evolving RNAs can provide specific 
biological behaviors associated with certain sequences, which in turn translates into the 
effect or association between phenotype (secondary structure) and genotype (primary 
structure). The in vitro evolution of ribozymes has provided better understanding on how 
natural RNA catalysts evolve. Previous in vitro isolation of a group of RNA-cleaving 
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ribozymes with a motif that is similar to the hammerhead ribozymes provides evidence 
that self-cleaving ribozymes have undergone convergent evolution in nature [7].  
The Bartel lab used in vitro evolution of ribozymes to prove the notion that RNA 
folds can evolve without the requirement of inactive intermediates [8]. They started with 
a class III RNA ligase evolved in vitro and an existing hepatitis delta virus ribozymes, 
and evolved these ribozymes so that they would approach each other in sequence space. 
Among the variants generated they found an “intersection” sequence that possessed both 
the ligase and the self-cleaving activity supporting the theory that natural ribozymes can 
evolve from a common ancestor even if they had different structural and functional 
characteristics. 
In vitro selection or directed evolution of nucleic acids involves many of the same 
steps that are operant during natural selection. In vitro selection of aptamers are DNA or 
RNA molecules that have been selected from random pools based on their ability to bind 
other molecules [9, 10]. We have previously selected for aptamers that bound to the 
protein lysozyme, and found that a single binding sequence largely dominated the 
population [11]. A small number of other species were also isolated, and their relation to 
the dominant sequence is shown in Figure 4.1. The sequences were compared to each 
other using their pairwise Hamming distances. Hamming distance is a method of 
sequence comparison that quantifies the dissimilarity between two oligomers by tallying 
up the number of nucleotide mismatches in their optimal alignment [12]. The 
dimensionality of the pairwise comparisons where then reduced using Principal 
Component Analysis. It is possible that this binding sequence represented a ‘global 
optimum’ for the selection.  However, because the selection experiment generated a fixed 
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clone, it was unclear whether the evolutionary landscape that connected nucleic acid 
sequences with lysozyme-binding function contained numerous, discrete local optima; or 
whether the landscape was similar to the ‘Mount Fujiyama’ selection function described 
by Kauffman [13]. More data is essential to populate the sequence space and determine 
the structure for functional sequence fitness landscapes by investigating how these 
sequences pan out during in vitro selections. Greater number of selection experiments is 
essential to elucidate the evolutionary pathways that the anti-lysozyme aptamers take in 
order to attain their final functionality. By probing sequence space with more data, we 
will be able to populate the fitness landscape providing us with the first glimpse into an 
evolutionary landscape using real experimental approach. Further analysis of the 
individual isolated sequences will be tested for their affinity towards the selected target 
and compared to previously isolated aptamers. The results can shed light into future 
selection process by taking into account the different factors, which can prevent the 
isolation of a better aptamer that might have been overlooked. With the advent of 
automated selection, it is possible to conduct theoretical studies utilizing experimental 
data to attain a more accurate model.  
As a first step towards experimentally probing the nature of evolutionary 
landscapes using the wet-lab approach, we started from several arbitrary sequences and 
selected for lysozyme-binding function. A random sequence population of nucleic acids 
was initially generated by a combination of chemical synthesis and enzymatic 
amplification. Traditional in vitro selection techniques would require weeks to months for 
one set of selections to be completed, hence, conducting the described selection 
experiments would prove to be unfeasible. To overcome this obstacle, a Biomek 2000 
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Laboratory Automation Workstation that has been outfitted was employed to carry out 
multiple in vitro nucleic acid selections in parallel. On the workstation, this population 
was parsed for function. In this instance, nucleic acids that can bind to an arbitrary target 
protein, lysozyme, were selected. After each round of selection, the selected nucleic acid 
binding species (also known as aptamers) were amplified by a combination of reverse 
transcription, PCR, and in vitro transcription. Automated in vitro selections allowed the 
generation of considerable amounts of experimental data in a short amount of time 
making the link between theoretical studies with real bench work data attainable.  
 
Figure 4.1. Aptamer sequences from the N30 pool selected against lysozyme. The 
isolated sequences were compared to each other based on their pairwise hamming 
distances. A principal component analysis was conducted for all the pairwise 
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comparisons to reduce the data’s dimensionality. The 2-dimensional projection of the 
PCA analysis is plotted on the x and z axis using Matlab. The vertical (y) axis is each 
aptamer’s fitness measure on the binding affinity of the species to the target lysozyme. 
During this individual selection one dominant clone was isolated. The dominant clone is 
highlighted in red and shows the highest level of fitness value as measured by their 
binding affinity to the target lysozyme [14]. 
 
In vitro selections are often carried out only once without partitioning the initial 
pool.  The isolated binding aptamer is assumed to be the fittest among the population 
because it is the sole aptamer isolated. In this experiment, it can be inferred that when 
given a chance to evolve, other species can be isolated. The results show that no two 
pools display the same behavior in terms of their evolutionary pattern from their binding 
trends. During in vitro selection, many different factors can prevent the isolation of the 
best binder. Some RNA aptamers that have better amplification capability might out-
compete other more stable structures that are unable to amplify as efficiently. By splitting 
the pools before the process of selection, we are allowing more room for other species to 
win in the competition shedding light into whether the previously selected winner is 
indeed the global optimal aptamer. This work is the progression from work found in the 
previous section (Chapter 3). Having overcome the contamination issues, we are 
confident in carrying out theoretical analysis of the data generated with more confidence. 
Our approach of first dividing the pool to eight different groups each with unique 
sequences without any overlap allows us to explore the evolution of aptamer fitness from 
different starting points in sequence space and a greater number of starting different 
sequence population. By exploring 8 different pools, we are also able to access a greater 
number of the pool’s population than conducting the selecting using one pool alone. This 
approach allows each sequence a greater chance to evolve its ability to bind to the target 
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of interest by giving them a greater chance to be found within each pool population. 
Figure 4.2A and Figure 4.2B compare traditional in vitro selections versus our own 
approach for exploring the aptamer sequence space. It can be discerned from the figures 
that by exploring evolutionary pathways based on a single pool selection, the results from 
the experiment can be biased and limited, since only limited amount of the population is 
accessible to the pool (Figure 4.2A). However, when a larger number of pools is tested, 
more sequences become available to undergo selection. This is a more comprehensive 
way for populating the aptamer space. 
 
Figure 4.2A. Traditional in vitro Aptamer Selections. Selections that are carried out 
usually explore and start from one single amplified pool and probe for function from that 
pool. The disadvantage of this approach is that only a small area of the sequence space is 





Figure 4.2B. In vitro Selection from a Divided Pool. When the initial pool is divided 
before amplification is introduced, we are able to explore a wider area in the sequence 
space. This is a more comprehensive way at exploring aptamer sequence space. 
RESULTS AND DISCUSSION 
For each pool that was harvested from Chapter 3 selections against protein target 
Lysozyme, sequencing of rounds 6, 12, and 18 were conducted. Individual clones were 
chosen from the last round of selection (round 18) from the sequence data and assayed 
for fitness (affinity towards lysozyme). All sequences were assayed in parallel with the 
previous selected lysozyme aptamer “Clone 1” [11]. 
 
POOL 1 FUNCTIONALITY ASSESSMENT 
Individual RNA clones were chosen from the round 18 sequences isolated 
previously as described in Chapter 3. Figure 4.3A shows the alignment of round 18 
sequences for Pool 1. The sequences chosen for subsequent fitness testing are highlighted 
in yellow. The approach taken at electing the sequences for testing was based on their 
frequency of occurrence. If there was a predominant clone, it was crucial to assess their 
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Figure 4.3A. Alignment of Pool 1 Round 18 Sequences. Clone highlighted in yellow 
are the chosen ones to undergo a binding assay. Primer binding regions are in maroon and 
flanked the random region of N40. Sequence families are grouped together and colored 
random region designates identical sequences. 
 
 The assays involved the incubation of radioactively transcribed RNA clones with 
the target protein at equimolar ratios (250 nM) in 100 uL of selection buffer. The 
reactions were then washed through a vacuum manifold sandwiching a nitrocellulose and 
a nylon membrane. All reactions were performed in triplicates so that standard errors 
could be obtained. Figure 4.3B shows the binding data for Pool 1 Round 18 selection. 
The clones isolated from Pool 1 were no better than the previously selected clone 1.  
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Figure 4.3B. Binding Data for Individual Clones from Pool 1 at Round 18. 
 
All clones, except for C12, had affinities to the target comparable to that of Round 18 
assayed as a pool. This data is not surprising considering the information about the drop 
in binding affinity that occurred when the selection went from round 12 to 18. This 
selection did not reach a level of pool enrichment that is often observed during in vitro 
selections of aptamers. 
POOL 2 FUNCTIONALITY ASSESSMENT 
 
 Since Pool 2 did not show any predominant sequence or common motifs, 
sequences were chosen at random. However, the presence of a drop in binding from 
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round 12 to round 18 made investigating clones in round 12 important. From the 
sequence alignments shown in Figure 4.4A of both round 12 and 18, there was a hint of 
species enrichment that was starting to take place, but the sequence clone (B4) 
disappeared by the time round 18 was reached. 
 Looking at the binding affinities (Figure 4.4B), it showed relatively high fitness 
for both round 12 clones. Not only were the numbers comparable to that of round 18, B2 
had an affinity equal to Clone 1 previously selected from the N30 pool. Even with such 
high affinity towards the protein target, these clones disappeared from the population at 
round 12. One would expect clone B2 to evolve and overtake the entire selection because 
of its high binding to Lysozyme as expected from traditional selection methods. The 
disappearance of such high binding molecule could be attributed to the limits of 
amplification during in vitro selections as discussed in Chapter 3. This data provided 
further evidence that stable, high performance sequences might be at a disadvantage 




Figure 4.4A. Alignment of Pool 2 Round 12 and 18 Sequences. Clones highlighted in 
yellow are the chosen ones to undergo a binding assay. Primer binding regions are in 
maroon and flanked the random region of N40. Sequence families are grouped together 




Figure 4.4B. Binding Data for Individual Clones from Pool 2 at Round 12 and 
Round 18. 
 
POOL 3 FUNCTIONALITY ASSESSMENT 
 
 Pool 3 sequence enrichment trends were very typical for that of a traditional 
selection (Figure 4.5A). Round 18 was predominantly populated by one single clone 
sequence. This dominant RNA was tested along with other sequence clones. Two of the 
isolated clones showed high binding, however, neither one of them were the dominant 
sequence (Figure 4.5B). This supports the notion that the frequency of a clone does not 
necessary mean that it has optimal functionality. Moreover, during in vitro selections 
many factors, in addition to just function, plays an important role in the deciding the 
species will come out being the winner. 
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Figure 4.5A. Alignment of Pool 3 Round 18 Sequences. Clones highlighted in yellow 
are the chosen ones to undergo a binding assay. Primer binding regions are in maroon and 
flanked the random region of N40. Sequence families are grouped together and colored 





Figure 4.5B. Binding Data for Individual Clones from Pool 3 at Round 18. 
POOL 4 FUNCTIONALITY ASSESSMENT 
At round 18 for Pool 4, there was a slight level of enrichment for a number of 
isolated individuals (Figure 4.6A). Although the pool itself did not show groundbreaking 
binding, the clones isolated; however, show binders that were comparable to Clone 1 
from the N30 pool selection. We were starting to see the ability to isolate aptamers to 
Lysozyme that showed affinities similar or even higher to that of Clone 1 by splitting the 




Figure 4.6A. Alignment of Pool 4 Round 18 Sequences. Clones highlighted in yellow 
are the chosen ones to undergo a binding assay. Primer binding regions are in maroon and 
flanked the random region of N40. Sequence families are grouped together and colored 
random region designates identical sequences. 
 
 
Figure 4.6B. Binding Data for Individual Clones from Pool 4 at Round 18. 
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POOL 5 FUNCTIONALITY ASSESSMENT 
Since there was no predominant family or sequence clone that was found in round 
18 in Pool 5 clones are chosen at random for assaying as shown in Figure 4.7A The pool 
itself bound at a high fraction. However the individual clones were not as impressive as 
one would have expected. A couple of clones showed binding fractions almost as high as 
that of Clone 1 (Figure 4.7B). Since no clear loss of complexity is observed for this pool, 
under normal circumstances, the selection of this pool would continue beyond round 18 
with increases in stringency. 
 
 
Figure 4.7A. Alignment of Pool 5 Round 18 Sequences. Clones highlighted in yellow 
are the chosen ones to undergo a binding assay. Primer binding regions are in maroon and 
flanked the random region of N40. Sequence families are grouped together and colored 




Figure 4.7B. Binding Data for Individual Clones from Pool 5 at Round 18. 
 
POOL 6 FUNCTIONALITY ASSESSMENT 
 Pool 6 showed a high level of enrichment. However, multiple species were 
becoming more frequent in the population at round 18 (Figure 4.8A). The binding data 
showed that not all of the species exhibited high degree of binding (Figure 4.8B). The 
majority of the clones bound at the same level as the pool itself only. This is another 




Figure 4.8A. Alignment of Pool 6 Round 18 Sequences. Clones highlighted in yellow 
are the chosen ones to undergo a binding assay. Primer binding regions are in maroon and 
flanked the random region of N40. Sequence families are grouped together and colored 





Figure 4.8B. Binding Data for Individual Clones from Pool 6 at Round 18. 
 
POOL 7 FUNCTIONALITY ASSESSMENT 
 Pool 7 remained diverse even at round 18 (Figure 4.9A). Not only was the pool 
still highly complex, the biding of Pool 7 at round 18 was only slightly above background 
(Figure 4.9B), which is reflected on the isolated clones as well. They all exhibited 
mediocre binding percentages. This pool is a great candidate to undergo further rounds of 
selection with increasing stringency needed. 
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Figure 4.9A. Alignment of Pool 7 Round 18 Sequences. Clones highlighted in yellow 
are the chosen ones to undergo a binding assay. Primer binding regions are in maroon and 
flanked the random region of N40. Sequence families are grouped together and colored 




Figure 4.9B. Binding Data for Individual Clones from Pool 7 at Round 18. 
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POOL 8 FUNCTIONALITY ASSESSMENT 
 Very high degree of enrichment occurred with Pool 8 as seen in Figure 4.10A. 
The isolation of comparable and some better binders to Clone 1 was supported by high 
degree of complexity reduction (Figure 4.10B). Their bound fractions were very similar 




Figure 4.10A. Alignment of Pool 8 Round 18 Sequences. Clones highlighted in yellow 
are the chosen ones to undergo a binding assay. Primer binding regions are in maroon and 
flanked the random region of N40. Sequence families are grouped together and colored 




Figure 4.10B. Binding Data for Individual Clones from Pool 8 at Round 18. 
MULTIVARIATE PROJECTION METHODS 
 
The main challenge in genotype space representation is the ability to display data 
from multivariate datasets. A method known as multivariate projection is widely used for 
the analysis and modeling of multivariate datasets. This method is used in the analysis of 
sequence space data presented in this work. The main multivariate projection method 
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applied in chemometrics is the Principal Component Analysis (PCA). This method is 
defined as a linear transformation that converts the data to a new coordinate, such that the 
greatest variance by any projection of the data comes to lie on the first coordinate (called 
the first principal component), the second greatest variance on the second coordinate, and 
so on and so forth. PCA reduces the dimension in a dataset by retaining those properties 
of the data set that contribute to the most variance also known as the "most important" 
aspects of the data.  
PCA is highly suited for the analysis of data that cannot be conducted using the 
traditional statistical standards. Common traits with biological datasets are that they 
contain more variables than observations where the information is noisy. Underlying 
structures and latent variables are important parts included in these datasets. A latent 
variable cannot be measured directly but is estimated as a linear combination of directly 
measured variables. A dataset consisting of N observations and K variables can 
theoretically be visualized as a plot of the N samples in a K dimensional space. However, 
the limitations of our cognitive abilities make it very difficult to visualize such spaces 
when K > 3 or more than 3 dimensions. The latent variables can be geometrically 
interpreted as vectors in the multidimensional space that describe as much as possible of 
the variation in the data and minimize the sum of the squared residuals. The combination 
of multiple components creates hyper-planes. Multivariate projection methods are 
transparent and can be easily interpreted and validated in depth. The dimensional 
reduction of components from the multidimensional space gives results that can be 
geometrically interpreted in two-dimensional and three-dimensional plots. Other methods 
used for modeling multivariate data are artificial neural networks (ANNs) and Support 
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Vector Machines (SVMs), which are referred to as nonlinear methods. Unlike in SVM 
and ANN, where data are implicitly transformed in the modeling process, PCA requires 
the data to be explicitly transformed or expanded with quadratic terms in order to handle 
nonlinearity. 
Figure 4.11 is a PCA analysis of the sequence data of the clones that have been 
tested for each pool. The analysis is conducted using PCOORD 
(http://www.hiv.lanl.gov/content/hiv-db/PCOORD/PCOORD.html). In summary, 
sequence alignments of the clones that have been assayed are submitted. A pairwise 
hamming distance matrix is generated and by utilizing sequence ordination [16] to obtain 
PCA values are obtained and plotted allowing 10 dimensions for the user to select in 
order to obtain a two-dimensional view of this multi-dimensional analysis.  
From the PCA analysis, pools selected that have reached some level of functional 
equilibrium by the appearance of dominant sequences in addition to displaying high 
degree of target affinity fall within a dimension. For instance, sequences isolated at round 
18 from Pool 2 fall almost in a linear function to the red line that is added to help with 
visualization. Pool 8 is another example of the appearance of several RNA sequence 
families at round 18. Pool 3 shows similar trend as that of Pool 2 and 8. Clone 1 is also 
plotted to show its position relative to other functional sequences. 
Although all the isolated clones (including the ones from Pools 2,3, and 8) have 
similar functions with comparable levels of binding capacity, they do not share common 
primary sequences. They can be as different from each other as some the sequences are 
from the previously selected Clone 1.  
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Figure 4.11. PCA Analysis of the Round 18 Tested Sequences. Two-dimensional view 
of the Principal Coordinate Analysis (PCA) is shown. Coordinates 1 and 2 are displayed. 
As can be inferred from the graph, most sequences are extremely different from each 
other as well as the previously isolated Clone 1. However, for pools 2, 3, and 8 where 
strong binders were isolated and families formed, their sequences are more alike within 
the pool as shown by the linear display of the aptamer layout. In conclusion, the 
traditional 1 pool 1 selection traditional method does not really allow for the isolation of 
the best true binder, as this analysis shows, the fitness landscapes still contains other 
sequences with functionality fitness comparable or even better than the previously 
isolated sequence. 
CONCLUSION 
From this analysis, it can be inferred that in vitro selections carried out with one 
single pool limits the window for achieving other equally good binders. Single selections 
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have limited evolutionary paths as well as nucleic acid species that can be explored. We 
have isolated aptamers that showed higher or equal degree of activity than was previously 
thought possible. If only the individual sequences within a population were given a 
chance to evolve without being constricted within one single pool, more areas of the 
functional and sequence space could be accessed. The data here shows that the fitness 
landscape of aptamers or unnatural sequences is not composed of that one single peak but 
rather multiple peaks. From the data presented here, there are certainly limitations to 
conventional in vitro selections at attaining the best aptamer. One of the biggest 
constraints is the replication efficiency for reactions conducted in vitro. This is another 
area that the lab has started to explore. 
  Even in these experiments, we might not have even found the optimal sequence; 
after all, there are constraints when performing in vitro selections that cannot replicate the 
real events that occur natural selection. In this work, we have confirmed that the 
straightforward single pool has a lot of limitations in terms of the number of sequences 
that it can be accessed and the limited number of species with good fitness that can be 
isolated. As the methods for nucleic acid space continues to be improved by in vitro 
selections, more questions can begin to be addressed such as whether methods to search 
the entire sequence space for functions can ever be attained. What are the difficulties and 
properties that hinder the evolution of a molecule for certain functionality in vitro? 
Understanding these aspects will eventually allow the scientists to faithfully replicate 
nature’s approach at generating molecular function.  
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MATERIALS AND METHODS 
INDIVIDUAL CLONE SEQUENCING 
 
Individual clones from each selected pool were isolated and sequenced.  Once the 
products are harvested from the robot selection process, a small aliquot from the RT-PCR 
reactions for rounds 6, 12, and 18 are amplified and then ligated into a thymidine-
overhang vector (TA Cloning Kit, Invitrogen). The templates that will undergo 
sequencing reactions are generated from colony PCR reactions [17] using standard M13 
reverse and forward sequencing primers that flank the insertion site of the TA vector. 
These PCR products are purified using a 96-well Multiscreen-PCR cleanup plate 
(Millipore). The integrity and size of the colony PCR products are visualized on a 4% 
agarose gel to ensure the success of template insertion. 
Sequencing reactions are performed using a CEQ DTCS Quick Start Kit 
(Beckman-Coulter). The reactions are performed as described by the vendor’s 
instructions. In summary, about 100 fmol of purified products are used as templates. The 
unincorporated dyes are with dry Sephadex G50 (Amersham Pharmacia) placed into a 
MultiScreen HV plate. The sephadex is hydrated with water for 3 hours at room 
temperature. The sequencing reactions are then loaded onto the columns and spun for 5 
minutes at 1,100 g. The samples recovered are then dried under vacuum and the pellets 
are resuspended in deionized formamide and developed on a CEQ 2000XL 8-channel 




Individual clones amplified from the colony PCR reactions using standard pool 
primers, in this case 42.40 and 20.40. The PCR reactions are ethanol precipitated, 
resuspended in water and quantitated on a 4% agarose gel using 100 bp quantitation 
standards (Gensura). The dsDNA are then transcribed in the presence of !-32P-labeled 
UTP. The generated RNAs are purified on an 8% polyacrylamide gel, eluted and ethanol 
precipitated. The concentration of the RNA products is determined using a 
Spectrophotometer. 
Aptamers are assayed for their affinity to the selected target Lysozyme as 
previously described [18] using a nitrocellulose (Schleicher & Schuell, Keene, NH) and 
nylon membrane (Amersham Pharmacia Biotech) sandwiched by a Minifold I filtration 
manifold (Schleicher & Schuell). The binding reactions conducted in triplicates using 
with equimolar amounts of RNA and Protein incubated in selection buffer at room 
temperature. They are filtered through the membranes with the selection buffer (20 mM 
Tris (pH 7.5), 100 mM NaCl, 5 mM MgCl2). Fraction of the RNA that binds to the target 
is computed using a PhosphorImager SI (Amersham Pharmacia Biotech) and calculated 
using the following formula: 
 
Fraction of RNA bound   =           RNA captured on nitrocellulose         . 
    RNA on nitrocellulose + RNA on nylon 




With the sequencing data, the random regions for the N40 selected pool are 
aligned with All nucleotide and amino acid sequences were aligned using a computer 
program (MacVector.) and visually inspected before analysis. The rationale for removing 
the constant regions is because they are static and does not contribute in the analysis of 
primary sequences variation. Moreover, by just analyzing the random region will provide 
a fair comparison of the isolated clones to the winning single clone for Lysozyme isolated 
from the N30 pool [11] because of differences in the constant regions. If the primer 
regions were left in the analysis, the difference genetic distance between the newly 
isolated clones from N40 will be overestimated because of the additional 60 base pair 
difference between the two selection pools. Precautions are taken to ensure the integrity 
of sequence data as previously recommended [19]. The diversity of the isolated 
sequences are calculated by analyzing their genetic pairwise Hamming distances, defined 
as the number of base differences between two sequences [12]. The Hamming distance is 
calculated based on the following formula: 
Hamming distance = (1-fraction of shared sites in two aligned sequences) x100 
 Once the pairwise distance matrix is generated, principal component analysis is 
carried out using the software PCOORD (available via the web: 
http://www.hiv.lanl.gov/content/hiv-db/PCOORD/PCOORD.html), which helps visualize 
the multidimensional variation in the sequences. PCOORD is useful at finding 
meaningful patterns in sequence data without any prior knowledge about the evolutionary 
history. It functions in summarizing the variations in the sequences and provides a plot in 
a limited number of dimensions. It uses a ordination, which is a method that analyses 
complex data sets to find the best way to describe multi-dimensional dataset [16].  
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PRINCIPAL COMPONENT ANALYSIS 
 
Principal Component Analysis (PCA) is used to obtain an overview of data, to 
find groupings, identify outliers and to generate variables that summarize the main 
sources of variation in the data and can be used in subsequent analyses. The easiest way 
to understand PCA is as a projection technique analogous to an ordinary window. The 
three dimensional reality is projected on the two dimensional window. The window is 
oriented so that as much as possible of the reality can be seen through it. The central idea 
of PCA is to extract a few, so-called, principal components or scores (t) describing as 
much as possible of the variation present in the data. The principal components are linear 
combinations of the original variables and are uncorrelated to each other. They can be 
imagined as mutually orthogonal lines in the multivariate space. As previously shown 
[20]:  
X = t1p’1 + t2p’2 + t3p’3 + …tNp’N + E = TP’ + E 
Here, N is the number of principal components and E is the residual matrix. For each 
component, t represents the scores vector and p’ the loadings vector. The principal 
components can be determined using the NIPALS algorithm [21] or by Singular Value 
Decomposition (SVD) [20]. The scores (t) show how the objects and experiments relate 
to each other. The loadings (p) reveal which variables are important for explaining the 
patterns seen in the score plot and can be geometrically interpreted as the angles between 
the principal component and the original variables. Analysis of the scores and the 
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Lung cancer is the most prevalent cancer in the world. It is divided into non-small 
cell lung cancer (NSCLC), which accounts for about 80% of the cases; and small cell 
lung cancer (SCLC) comprising the other 20% [1]. Most of the lung cancers are grouped 
under NSCLCs. They are grouped because treatment regimen and prognosis are similar. 
There are 3 predictors, termed TNM (tumor, node, metastasis) state at diagnosis, that are 
used for survival prediction of NSCLCs [2]. Available treatments are usually ineffective 
or excessively toxic.  SCLC is considered the more aggressive type of lung cancer with 
very poor prognosis. Metastases start from the lymph nodes then quickly spreads to the 
lung, liver, adrenal glands, bone, bone marrow, and brain. Early detection is crucial for 
this cancer, but the lack of adequate tumor markers makes it a very daunting task. Hence 
developing diagnostic tools to identify these primary cancers can highly improve 
prognosis [3]. 
Finding biomarkers to aid in early detection and improving diagnosis has been a 
focus of many researchers [4]. The identification of molecular alteration to all tumors in 
general as well as signals that can subcategorize the cancers can be useful for diagnosis, 
treatment regime, and therapeutic assessment.[5]. However, because of the sheer number 
and the level of heterogeneity across the different lung cancers make the process a highly 
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complex procedure [6, 7]. Cancer biomarkers can be divided into serum biomarkers, 
tissue biomarkers and sputum biomarkers [8].  NSCLC and SCLC have slightly different 
biomarker expressions. Neuroendocrine cells such as neuron-specific enolase (NSE), 
chromogranin A (ChrA), bombesin-like gastrin-releasing peptide, and BB isoenzyme of 
creatine kinase are all specific to SCLC [9]. For NSCLC, most of the makers include 
proteins specific for cell cycling, growth factors and their receptors [10, 11]. 
APTAMER AND DIAGNOSTICS 
 
Aptamers are very effective tools that can be applied in the form of small-
molecular detection probes, target inhibitors or target binders. Their relatively small 
nature allows for easy manipulation and conjugation of these aptamers with other 
molecules such as quantum dots, oligonucleotides, nanoparticles and siRNA delivery[12, 
13]. Aptamers also serve as excellent biomarker sensors due to their highly specific 
nature [14].  The ability to select aptamers against simple or complex targets and their 
seemingly pluripotent binding abilities make them excellent reagents for the study, 
diagnosis, and perhaps even therapy of cancers, as reviewed by Cerchia et al.[15].  In 
fact, selection experiments have yielded RNA and DNA aptamers that can bind to cell 
surface targets on tumors [16-19].   In each instance, the aptamers were able to 
selectively bind transformed cells but not normal cells.  For example, Hicke et al., [18]  
targeted human U251 glioblastoma cells with a 2’-fluoropyrimidine, modified RNA pool.  
Selected, modified RNA aptamers were found to bind the extracellular matrix protein 
Tenascin-C (TN-C), a protein that is believed to be a hallmark of the onset and metastasis 
of cancer.  The aptamers formed complexes with TN-C that had a dissociation constant of 
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5 nM.  The aptamers also bound tumor tissue expressing Tenascin-C, but did not bind 
tissue that lacked TN-C.  In fact, the aptamer was also able to discriminate (by 20-fold) 
against mouse TN-C, even though this protein shared 98% sequence identity with the 
human protein.  
Another example, Lupold et al. [19] targeted prostate-specific membrane antigen 
(PSMA), which is a membrane-bound glycoprotein that is found in prostate epithelial 
cells and overexpressed by prostate cancers.  In fact, its detection in increased quantities 
is considered a hallmark of the disease. Two aptamers were selected from a 2’-
fluoropyrimidine modified RNA library that spanned 40 random sequence positions.  The 
aptamers were distinct from one another and likely bound different epitopes of the PSMA 
antigen.  The aptamers could inhibit the peptidase activity of PSMA with Ki values in the 
2-10 nM range.  Fluorescently labeled aptamers were also shown to bind to a prostate 
tumor line (LNCaP) that normally overexpresses PSMA, but not to PC-3 cells, a different 
prostate tumor line that lacks this antigen expression [20, 21].  
Blank et al. [16] [16] carried out a selection against rat endothelial cells 
immortalized with adenovirus, and isolated a single-stranded DNA aptamer that proved 
to be specific for glioblastoma.  The aptamer was found to bind to the protein pigpen, 
which plays a role in angiogenesis by regulating endothelial cell proliferation.  Pigpen 
expression is up-regulated in actively dividing cells and is down-regulated as they 
become confluent, suggesting that pigpen helps regulate endothelial cell differentiation 
[22]. The aptamer were able to label the microvessels surrounding the rat glioblastoma, 
but not microvessels in normal, mature brain vasculature.  As was the case with anti-
PSMA aptamers, the anti-pigpen aptamers could be fluorescently labeled and used for 
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contrast staining of transformed cells versus normal cells.  Finally, DNA aptamers that 
were selected against leukemia cells were specific for T-cells and not B-lymphoma cells 
[23]. 
Such a diversity of biomarkers exist among lung cancer lines that honing down on 
a particular target for the disease is very difficult. However the ability of aptamers to 
target broad range of targets make them great candidates for this purpose. Selecting 
aptamers against lung tumor lines might seem like a leap of faith because of cell 
heterogeneity. Aside from such difference, there is also a great degree of similarity 
among the cells, especially SCLC, NSCLC and normal lung lines. The idea that certain 
growth factors are overexpressed is no longer a feature to cancerous cells [2]. For clinical 
applications, the challenge is to develop biosensor that can distinguish among different 
type of lung cancer, but not so unique that it will only be able to identify a single type of 
cell line, which will highly limit its utility. 
CELL LINE SIGNIFCANCE 
 
Three lung tumor cell lines that differ in their Epidermal Growth Factor Receptor 
(EGFR) expression were chosen as targets for selection.  NCI-H358 is from a non-small 
cell lung cancer and expresses wild type EGFR.  A brief summary of the cell lines is 
shown in Table 4.1. NCI-1650 is from a bronchoalveolar carcinoma and expresses a 
mutant form of EGFR (in-frame deletion delE746-A750). NCIH526 is from a small cell 
lung cancer (SCLC) cell lines and expresses low to undetectable levels of EGFR.   The 
first two lines are adherent, but NCI-H526 is a suspension culture. Many agents available 
target the EGFR and have made more promising results of NSCLC treatment. In addition 
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to the monoclonal antibody treatments, two available EGFR tyrosine kinase inhibitors, 
erlotinib and gefitinib, have elicited good response in patients with NSCLC relapse [24, 
25]. When combined with chemotherapy, patients under erlotinib had a longer survival 
[26]. Figure 5.1 is a summary of the different targets for the therapy that are available up 
to date for EGFR. 
 
Figure 5.1. Therapeutic Agents Against EGFR. Multi-targeted therapy is one of the 
golden rules against lung cancer. Different therapeutic agents are utilized in conjunction 
to target different areas of the cell. Monoclonal antibodies (Cetuximab) compete with 
extracellular ligands to prevent the dimerization of the EGFR. New intracellular 
inhibitors for the tyrosine kinase domain (Gefitnib and Erlotinib) stop downstream 
signaling cascades. Finally, Radiation/Chemotherapy targets the nuclear cellular 
functions stopping cell cycling activities. 
 
All these facts are the premise for our choice of lines to start our investigation of aptamer 
selection against lung cancer cells.  
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Table 5.1. Cell lines Used for Selections 
Results and Discussion 
 
The first step in developing biosensors for such a high variety of lung cancer cells 
is the being able to isolate aptamers that will be specific for each type of lung cancer 
class. In this report work, we tailor make a selection protocol to select aptamers that can 
distinguish between cancer cells and normal lung cells; and aptamers that can 
differentiate between NSCLC and SCLC using a 2’F modified RNA aptamer pool with 
30 nucleotides in random region. 
Our first approach was conducting direct selection against individual cells. The 
process of cell surface selection against epithelial cells is illustrated in Figure 5.2. A pool 
of nuclease resistance RNAs are incubated with cells that are grown to about 85% 
confluence for 3 hours. The cell undergoes a series of wash steps with PBS to rid of the 
unbound RNA aptamers. The winners are isolated by trypsinizing the cells and washed 
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further with PBS. The isolated cells are then lysed to isolate any remaining RNAs that 
may have internalized. The isolated RNAs undergo a series of amplification steps to 
generate the enriched pool for the next round of selection. For suspension cells, the 
process is similar except for the “(+) trypsin,” which is by-passed.  
 
Figure 5.2. Cell Surface Selection Schema. 
SCLC (H526) SELECTIONS 
Selections against suspension cells H526, which are small cell lung cancer cells, 
are carried out without for 9 rounds and assayed for binding. The assays are out carried 
by incubating radiolabeled modified RNAs against the cells. Figure 5.3 shows the result 




Figure 5.3. Aptamer Selections Against H526. All the clones isolated from round 9 of 
the selection showed significant affinity towards H526 cells relative to background. 
Previously selected aptamer A9 [19] was assayed against LnCAP cells to serve as a 
positive control. 
 
H526 data shows that by round 5, the aptamer pool is showing significant improved 
affinity towards the cell. Round 9 improvements from round 5 is no longer as drastic. The 
pool from Round 9 is further sequenced and characterized. The sequences obtained are 
displayed in Figure 5.4. The pool complexity is relatively high. There is no formation of 
sequence families or common motifs across the different sequences. This diversity in the 
population is of no surprise because the selection is carried out against a complex target. 
The first ten clones (clones 1-10) are selected to measure specificity towards H526 and 
another cell H358, which is a NSCLC cell.  The results for this assay are displayed in 




Figure 5.4. H526 Selected Clones at Round 9. The primer binding regions are colored 
maroon and the random regions are in black. The graph shows that the pools remains 
highly complex and there is no clear appearance of motifs or the formation of specific 
sequence families. 
 
All clones are assayed in triplicate to generate the error bars. Every clone shows a 
significant increase in affinity to the targeted cell relative to background. However, none 
of the clones binding is a prominent as that of clone 2. In addition, the isolated clones are 
also incubated with H358 to test whether they show any affinity to a NSCLC cancer cell. 
The data shows no specificity towards the non-selected target at all. It appears that the 





Figure 5.5. Cross Reactivity Assay for H526 Selected Aptamers. The assay shows the 
binding affinity of individual clones isolated from the round 9 selection. Every clone 
shows higher binding to the specific cell relative to background. However, clone 2 shows 
the greatest improvement in binding. Moreover, most of the clones show little to now 
binding to the non-specific cell H358. Similar to Figure 5.3, PSMA aptamer is used as a 
positive control for the assays. 
 
Based on these binding assays, the next step is to assay these clones to test their 
ability to differentiate between NSCLC and SCLC cells. The clones selected for the next 
set of assay are picked based on their affinity to H526; only the 6 best binders are 
selected.  Additional cell lines are added to further evaluate these clones specificity. Two 
additional SCLC cells lines along with 4 different NSCLC cell lines are used in the test. 
Figure 5.6 shows an overview of the cells used in the assay for determine verify these 
clones specificity towards SCLC.  In summary, each individual point tested contains a 
cocktail of equal amounts of the different cells.  
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Figure 5.6. Assay Set-up for Aptamers against SCLC and NSCLC. A cocktail 
composed of 3 different cell lines for each category of lung cancer cell is used for 
determining the binding affinity of each individual clone.  
 
The results for the individual clone assays from round 9 against a cocktail of 
SCLC and NSCLC are shown in Figure 5.6. All the clones tested here except for clone 8 
showed high specificity towards the cocktail of SCLC cell lines versus the NSCLC 
cocktail. Such a high degree of specificity towards SCLC as opposed to NSCLC can be 
attributed to the biomarkers that are specific for each type of lung cancer. For example, 
neuroendocrine cell markers for the SCLC [9] and growth factors for NSCLC to name as 
previously described [10, 11]. According to the data, it appears as though the great 
distinctions among these two type of cells is different enough that isolating aptamers that 
would distinguish between these two cancer categories did not need the introduction of 




Figure 5.7. Aptamers Against and SCLC and NSCLC. Of the clones tested, only 
Clone 8 did not distinguish between SCLC cocktail and NSCLC cocktail of cells. Each 
cocktail contains 3 different cell lines. 
SELECTIONS AGAINST H358 AND H1650 (NSCLC) CELLS 
Initially selections are carried out as described in Figure 5.2 for each individual 
cell. Selections against H358 and H1650 are assayed at after reaching round 15 and 8 
respectively. An assay of the last round of selection of each pool is assayed against 
different NSCLC cell lines and normal lung cells. The data is displayed in Figure 5.8. A 
former graduate student Ted Chu has conducted selections against A549. All pools have 
binding above that of background against all cells. However, because of the amount of 
homogeneity among the NSCLC cells and even the normal cells, the pool is unable to 
differentiate between these cells. Even though, the RNA pool selected against A549 has 
higher specificity towards the selected target, the pool’s affinity towards the other cells 
remains significantly above background. To further investigate whether we can 






Figure 5.8. Cross Reactivity Testing. The last round of selection for each pool is 
labeled and assayed against a variety of cells. The figure shows that there is not a 
significant level of discrimination of the aptamer pool against other cell types that were 
not selected for. The high level of homogeneity between the variety of NSCLC and 
normal lung cells makes it impossible for the RNA pools to differentiate them. The 
“normal cell” is a cocktail of 3 different normal lung lines: MRC-9, NHBE, and CCD-
Lu16. 
 More tailoring of the selection was further conducted to isolate aptamers that 
could specifically differentiate between normal and cancer cells. Understanding how to 
customize selections for a specific purpose is crucial in developing aptamers especially 
for such a complex target that can both be homogenous and heterogeneous.  Starting back 
from round 10 of the RNA that have been selected against H358, additional selections 
against H358 were conducted. Negative selections against another NSCLC cell  (H1650) 






Figure 5.9. Additional H358 Selections. Additional selections are introduced to tailor 
generate aptamers that can distinguish particular lines of interest (circled in red). Instead 
of restarting the selections from round 0, all new selections are initiated from round 10 of 
the selected pool. The population of pool in round 10 is still very diverse as verified 
through sequencing of the pool. 
 
The purpose of introducing negative selections was to investigate the degree of 
selection fine-tuning that was needed to isolate the aptamers. This was important because 
of the large variation and similarity among lung cancer and normal cells. Negative cell 
selections involved an extra step as shown in Figure 5.10. The initial incubation of the 
pool took place with the non-specific target; in this case it would be H1650 or a cocktail 
of normal lung cell lines. The cells were then washed and the non-binders were then 




Figure 5.10. Negative Selection of Aptamers Against Cell Surfaces. Negative 
selections involve the incubation of the pool with the non-targeted cells, and the non-
binders recuperated from there are then incubated with the target of interest. 
 
The first negative selection involved selecting for aptamers that could distinguish 
between two different NSCLC cell lines as a proof of principle for the efficiency of 
isolating aptamers with particular specificity. The results are summarized in Figure 5.11. 
As the illustration shows, at round 10 of the selections against H358 and before the 
introduction of negative selections, the pool has an increased affinity towards H358 cells 
relative to round 0. However, this pool also displayed increased binding towards non-
specific cells such as H1650, H526, and normal lung cell lines. Another interesting 
observation was that selections against this NSCLC cell yielded a pool that had an 
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affinity towards the SCLC cell, H526. At round 15, after the introduction of negative 
selections against H1650, the affinity of the final pool towards H1650 was highly reduced 
as expected. Moreover, the pool’s affinity towards the SCLC cells was reduced as well. A 
plausible explanation for the sudden reduction in binding towards H526 could be 
attributed to the event that the negative selection reduced the population complexity and 
the amount of the pool going into the targeted cell. This event allowed for the increase in 
the stringency of the selection indirectly against H526 cells. The obvious differences 
between NSCLC and SCLC were prominent enough that by merely increasing the 
selection pressure of reducing the pool size was sufficient to isolate a pool that preferred 
the one cell over the other without negative selections. Unfortunately, the round 15 pool 
was unable to distinguish between H358 and normal cells. It could be inferred that 
normal cells shared more similarities with NSCLC cells than with SCLC cells. It has 
been shown previously that no morphological differences were observed between 
NSCLC lung mouse lung cell lines and normal mouse lung lines [27]. 
 
Figure 5.11. H358 Selections with Negative Selections against H1650 Cells. The 
introduction of negative selection against H1650 cells highly reduced the round 15 pools 
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ability to recognize H1650 cells. Normal cells are composed of a cocktail of MRC-9, 
CCD-Lu16, and NHBE cells. 
 
The next step was to do H358 selections with the introduction of negative 
selections against a cocktail of normal cells. Being able to isolate aptamers that can 
distinguish between cancerous versus non-cancerous cells has more clinical relevance 
than purely distinguishing between different cell lines. The results from this selection are 
shown in Figure 5.12.  The assays showed that before the introduction of negative 
selections against normal lung cell lines at round 10, the pool was unable to differentiate 
between these cell lines. However, after negative selections were introduced, the pool 
showed increased specificity towards the targeted cells H358. 
 
Figure 5.12. Binding Assays of H358 Selections. The negative selections against the 
normal cells were introduced after round 10. At round 15 the pool was labeled and 
assayed for specificity against H358 and the cocktail (MRC-9, CCD-Lu15, NHBE) 
cocktail of normal cells, the pool showed significantly higher specificity towards H358 
cells.  
 
The round 15 pool of this selection was cloned and sequenced. The sequences obtained 
are shown in Figure 5.12.  Similar to H526 selections, the isolated clones were all 
distinct form each other and no common motifs were found. This was also an indication 
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of the level of heterogeneity and complexity of the targets.  The first 10 individual clones 
(highlighted in yellow in Figure 5.13) were further tested for specificity. The results are 
shown in Figure 5.14. With the exception of two clones isolated, E7 and D6, the majority 
of the clones showed a high degree of preferential binding to H358 cells. The purpose of 
isolating these clones was to potentially serve as biosensors for the detection of tumor 
cells versus normal cells for our collaborators at MD Anderson. The next step that they 
are planning on undertaking is to label these aptamers and test them against their home 
made tissue arrays. 
 
Figure 5.13. Individual Clones from H358 Selections with Normal Cells as Non-
specific Targets. Constant regions are in maroon and the N30 random region are colored 




Figure 5.14. Round 15 Binding Assay Profiles. Individual clones from the R15 
selection of H358 cell with negative selections against normal cells show high specificity 
towards the selected cells with the exception of two clones. 
 
 We have been able to isolate aptamers that were able to distinguish between 
SCLC and NSCLC cells by doing a traditional cell surface selection against an SCLC cell 
(H526). These aptamer can potentially function as biosensors for the early detection of 
cancer cells and identify whether the cancerous cells are SCLC or NSCLC. The 
importance of this type of distinction is that it will allow clinicians to apply appropriate 
therapy. Because of the uniqueness biomarkers of SCLC cells, no negative selection was 
needed to isolate the aptamers that could discriminate against other cells. When tested 
against other SCLC cells, some of the aptamer were also able to recognize them. This 
makes them very powerful tools, because being able to identity a particular category of 
cancer is useful for clinical aspects than being able to identify one single cell line. 
However, more work should be involved the evaluation of a larger number of SCLC cell 
lines to determine whether the aptamers ability to recognize these cells are global. 
Testing these aptamer on human lung tissues will further support their potency for 
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clinical use. Due to the limitations in the lab, our collaborators from MD Anderson will 
be conducting these studies. 
 From the NSCLC cell selections, the outcomes were not as clean cut. Since 
NSCLC makes up more than two thirds of the lung cancers, the level of heterogeneity 
among them is obvious. The aptamers isolated from positive selections alone had a high 
level of cross-reactivity towards other cancerous and non-cancerous cells. Such wide 
range of recognition renders these aptamers useless. We tested how negative selections 
could alter the outcomes of the aptamers isolated. From our work, the introduction of a 
non-specific targeting step produced aptamers that were able to highly discriminate 
between these cells but not others. For example, the negative selections conducted against 
H1650 yielded aptamers that were highly specific to H358 and not H1650. However, 
these aptamers also recognized normal lung cell lines. By introducing negative selections 
against normal cell lines, we were able to isolate specific aptamers that recognized H358 
with high specificity. These aptamers were generated with the purpose of having them 
tested against tissue arrays that have been generated by Dr. Wistuba at MD Anderson to 
assess whether they will be able to distinguish between normal and NSCLC cell in tissue. 
CONCLUSIONS  
We have been able to tailor the selection process to isolate specific aptamers for 
our own purpose. However, there are still a lot of cells and more aptamers from specific 
cancer types may be needed to serve in lung cancer diagnostics.  Another challenge is 
that most aptamers that are carried out against cell lines might not be functional against 
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isolated tissues. The testing for the isolated aptamer from these selections against tissue 
samples will further validate the method that we have improved. 
The versatility of tailoring aptamers to specific targets is well known. Using 
aptamers to target cell surface markers have been conducted in various manners included 
direct cell surface selections [28-30], or selecting a purified cell surface protein [16, 19, 
31].  There are advantages and disadvantages to both forms of aptamer selections. The 
downside of directly selecting against cell surface is that the aptamers’ targets are not 
known, and additional steps are needed to determine the target. Selecting against purified 
protein may produce aptamers specific to the protein; however, they might not recognize 
the protein in its native form found on cancer cell surfaces.  
There are a large number of variables that can affect the success of a selection 
experiment. Very few selections target heterogeneous whole cells surfaces and thus the 
parameters that influence the selection are not well understood.  Understanding and 
controlling these variables will help maximize the chances of success with a wider range 
of tumor antigens and cells. The level of complexity and the number of available lung 
cancer cell lines poses an even greater challenge to isolate specific targets without a detail 
understanding of the fine-tuning that are required.  
FUTURE DIRECTIONS 
 
Because of the large number of selections that are needed to reach an optimal 
selection method for isolating useful aptamers for lung cancer cells, automating this 
process will prove to be highly useful. I have developed a protocol that will permit the 
Tecan Genesis (Figure 5.15A) and the Biomek 2000 to carry cell surface of SCLC 
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suspension cell lines. Letha Sooter had previously configured the Tecan Genesis 
workstation to carry out ssDNA selections [32]. For the purpose of cell selections a lot of 
modifications are needed to accommodate the selections. I designed a flow chart of the 
steps and processes that will take place when cell surface selections are translated into an 
automated workstation (Figure 5.15B). The selection will start with the incubation of the 
RNA with the cells that are acquired from a source that has refrigeration. Since selections 
are require about 16 hours to complete 6 rounds of selections, it is not possible to have 
the cells remain at room temperature for such an extensive period of time. The reaction 
will then be transferred to a partition area where the non-binders will be removed from 
the winners in the selection. The winners will undergo a series of amplification steps and 
a fraction of the RNA isolated will undergo the next round of selection.  
 
 
Figure 5.15A. Tecan Genesis Workstation. This workstation is outfitted with many 
third party instruments that are essential to carry out in vitro selections. The advantage of 
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the Tecan over the Biomek 2000 is the ability to carry out selections against 96 targets as 
opposed to only 8 in parallel.  
 
When designing the steps involved in robotic selections, it is very important  to 
take into account the instruments and consumables that can be outfitted on the 
worksurface. Moreover, the material of the consumables plays a crucial role for the 
selection outcomes. Once the steps and the consumables are determined, it is necessary to 
equip the worksurface with the required components as shown in Figure 5.15C. A dry 
run of this protocol has been conducted already. We currently have a high school student 
Daniel Winkler, who will continue working on programming the platform and further 
enhance the process from the existing skeleton found on the robot. 
 
 
Figure 5.15B. Flow Chart of the Automated Cell Surface Selection Process. The 
process involves like normal selections the incubation of the RNAs with the target cells. 
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However, it is imperative to have the cells stored in a place that ensures their integrity for 
a period of over 16 hours for 6 round of selections. Alternatively, 3 rounds of selections 
can be carried in half the amount of that time so that new cells can be fed preserving the 
health of the mammalian cells. 
 
Figure 5.15C. Tecan Genesis Worksurface Layout. Model of where the different plate 
from Figure 5.15B will be placed on the worksurface. The rationale and critical aspect of 
the plate locations is to ensure that the movement of the robot arms is as uni-directional 
(left to right) as possible without the back and forth toggling. This will ensure that less 
contamination will take place during the selection. 
 
MATERIALS AND METHODS 
CELL LINES: 
 
Lung cancer cell lines H358, H526, H1299, H1650, A549, H82, H209 are obtained from 
ATCC (Rockville, MD). Normal lung lines NHBE, CCD-Lu16, MRC-9 were obtained 
from our collaborators Dr. Jack Roth at MD Anderson Cancer Research Center. All cells 
well cultured according to ATCC instructions, except for NHBE, which is cultured 
according to Clonetics instructions. 
IN VITRO TRANSCRIPTION OF APTAMERS AND PURIFICATION: 
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Aptamer library of DNA with random insert of 30 nucleotides was synthesized 
following: N30 pool (GGG AAT GGA TCC ACA TCT ACG AAT TCN NNN NNN 
NNN NNN NNN NNN NNN NNN NNN NNT TCA CTG CAG ACT TGA CGA AGC 
TT), 41.30 (GAT AAT ACG ACT CAC TAT AGG GAA TGG ATC CAC ATC TAC 
GA), 24.30 (AAG CTT CGT CAA GTC TGC AGTGAA). The 2'F-RNA library was 
generated by T7 in vitro transcription in transcription buffer (4% (w/v) polyethylene 
glycol 8000, 40 mM Tris-HCL (pH 8.0), 12 mM MgCl2, 5 mM DTT, 1 mM spermidine 
chloride, and 0.002% Triton X-100) with 4 mM 2'Fluorine-CTP (2’F-CTP), 4 mM 
2'Fluorine-UTP (2’F-UTP), 1 mM ATP and 1 mM GTP using a Y639F T7 RNA 
polymerase. Adding DNase then digests DNA templates.  Labeled RNA is then purified 
with an 8% polyacrylamide gel, eluted in water at 37°C overnight, ethanol precipitated 
then resuspended in water and quantitated with a spetrophometer.  For radiolabeled 
aptamers, 5 µCi of !-
32
P-labeled GTPs are be added to the transcription.  
APTAMER SELECTION: 
 
In the initial cell surface selection, 2’F modified RNA aptamer pool (3 mg) is 
incubated with cells. After incubation, unbound cells are washed away and the RNAs are 
isolated by first trypsinizing the cells and then resuspending them in PBS. The cells are 
then washed 3 times with 1 ml of binding buffer.  The cells are then lysed with 300 ml of 
trizol (Invitrogen, Carlsbad, California) at room temperature for 5 minutes, followed by 
standard phenol/chloroform extraction, and ethanol precipitation.  The recovered aptamer 
are suspended in reverse transcription/PCR buffer (5X RT/PCR buffer:  10 mM of Tris 
pH 8.4, 500mM of KCl, 160mM of MgCl2, 5% of Acetamide, 0.5% of Non-idet P40 and 
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2mM of dNTP).  The reaction is denatured at 70
o
C for 5 minutes and cooled to room. The 
next step involves the addition of AMV Reverse Transcriptase (USB Corporation, 
Cleveland, Ohio) and Taq DNA polymerase (Invitrogen, Carlsbad, California). The 
reaction undergoes a reverse transcription at 50
o
C for 10 minutes and then PCR amplified 
for 20 cycles (15 sec at 94
 o
C, 15 sec at 45C and 72
 o
C  at 60 sec).  The products are then 
ethanol precipitated, suspended in water and measured according to efficient coefficient 
(720700 L/(mole*cm)) at OD260). Transcriptions are further carried out to generate the 
enriched pool for the next round of selection.   
CHARACTERIZATION OF INDIVIDUAL CLONES 
 
DNA generated from selection were cloned, sequenced as previously described 
[33].  3x10
5
/50 ul of cells in PBS with 5mM MgCl2 are incubated with 
32
P-labeled 
aptamers for 30 minutes at room temperature, followed by wash step with 100 uL of PBS 
with 5mM MgCl2.  Cells are then resuspended in 100 uL of PBS with 5mM MgCl2 and 
filtered through the filtration manifold (Minifold I filtration manifold, Schleicher & 
Schuell, Keene, NH) with Hybond-N+ nylon transfer membrane (Amersham Pharmacia 
Biotech).   The binding of each aptamer is computed by using a PhosphorImager SI 
(Amersham Pharmacia Biotech) by comparing the radiation intensity from its original 
concentration with the signal that remains from cell suspension. 
 
 
The work presented in this Chapter is not complete due to submission dates of 
dissertations of the Graduate School. Regardless, the continuation of this work will 
proceed in a publication-oriented manner. Mass Spec experiments will be carried out to 
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determine the surface markers that the aptamers are recognizing. Another graduate in the 
laboratory will continue carrying cell surface selections against lung cancer cells and 
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